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ABSTRACT
Akt and the Wnt pathway, two cascades that regulate GSK-3, have been implicated in
schizophrenia and antipsychotic drug action. Although it is known that antipsychotic
drugs alleviate psychosis by blocking the dopamine D2 receptor (D2DR) and that
metabotropic glutamate receptor 2/3 (mGluR2/3) agonists may improve some of the
symptoms of schizophrenia, it is unclear if both classes of drugs exert their effects
through Akt, GSK-3 and/or the Wnt pathway or if changes in these pathways are
mediated through the D2DR and mGluR2/3 respectively. In addition to antipsychotics,
mood stabilizers and antidepressants also target GSK-3, suggesting that there must be
something unique in the way GSK-3 is targeted by antipsychotics since neither mood
stabilizers nor antidepressants alleviate psychosis. The current study examined whether
Akt and the Wnt pathway are regulated by the D2DR and mGluR2/3 and investigated the
role of Akt and Dvl-3, a key activator in the Wnt pathway, in regulating GSK-3 in the rat
brain. The study also compared the effects of antipsychotic, mood stabilizers and
antidepressants on Akt and Wnt pathway proteins to determine if antipsychotics have
unique effects on these signalling proteins. Results showed that raclopride (D2DR
antagonist) regulated Akt and the Wnt pathway via Dvl-3 and the response was identical
to antipsychotic treatment. Administration of the mGluR2/3 agonist, LY379268 also
targeted Akt and the Wnt pathway and induced a similar response as antipsychotics. In
addition, repeated amphetamine treatment, an established animal model for the positive
symptoms of schizophrenia, quinpirole (D2DR agonist) and LY341495 (mGluR2/3
antagonist) induced similar changes in Akt and Wnt signalling that parallel alterations
reported in schizophrenia.

Furthermore, systemic inhibition of GSK-3 was able to
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attenuate the increase in locomotion induced by LY341495, a behavioural measure that
models the positive symptoms of schizophrenia. The study also showed that clozapine
and haloperidol (antipsychotics) induced a common Wnt response that was not mimicked
by the mood stabilizers or antidepressants tested but that all neuropsychiatric drugs tested
induced changes in Akt. Collectively the data shows that the Wnt pathway is regulated
specifically by drugs with antipsychotic properties and may represent a novel target for
pharmaceutical intervention.

Keywords: Antipsychotic drugs, schizophrenia, dopamine D2 receptor, metabotropic
glutamate receptor 2/3, Wnt pathway, Akt pathway, Glycogen synthase kinase-3

iv

CO-AUTHORSHIP
Chapter 2 entitled “Alterations in GSK-3 and Akt signalling induced by the
dopamine D2 receptor are mediated by Dvl-3” was written by L. Sutton with input from
Dr. Rushlow and all studies were performed by L. Sutton. Chapter 3 entitled “The effect
of neuropsychiatric drugs and amphetamine on GSK- 3 related signalling” was written by
L. Sutton with input from Dr. Rushlow and all studies were performed by L. Sutton.
Chapter 4 entitled “Regulation of Akt and Wnt signalling by the group II metabotropic
glutamate receptor antagonist LY341495 and agonist LY379268” was written by L.
Sutton with input from Dr. Rushlow and all studies were performed by L. Sutton.

v

ACKNOWLEDGEMENTS
First and foremost, I want to thank my supervisor, Dr. Rushlow for his guidance
and support during the course of my doctoral degree. Dr. Rushlow has given me a strong
foundation to pursue my research career and has also encouraged me to do so.

I

appreciate all the contributions of time, ideas and knowledge to make my Ph.D.
experience productive and rewarding. The enthusiasm Dr. Rushlow has for his research
is contagious and motivational for me, even during tough times in my Ph.D. pursuit. I
would also like to thank the members of my advisory committee Drs. Belliveau and
Laviolette for their valued advice and constructive criticism. I am also thankful for the
excellent example they have provided as successful scientists and mentors.
On a personal note, I would like to thank my parents for their consistent
encouragement.

To my supportive and encouraging husband, Liam whose faithful

support especially during the final stages of my thesis Ph.D. is so appreciated. Thank
you.

vi

TABLE OF CONTENTS
TITLE ................................................................................................................................. ii
ABSTRACT....................................................................................................................... iii
CO-AUTHORSHIP ............................................................................................................ v
ACKNOWLEDGEMENTS............................................................................................... vi
TABLE OF CONTENTS.................................................................................................. vii
TABLE OF FIGURES....................................................................................................... xi
LIST OF APPENDICES.................................................................................................. xiii
LIST OF ABBREVIATIONS.......................................................................................... xiv
CHAPTER ONE: Introduction ....................................................................................... 1
1.1 SCHIZOPHRENIA.................................................................................................. 2
1.1.1 Epidemiology and clinical description of schizophrenia .................................. 2
1.1.2 Etiology of Schizophrenia................................................................................. 3
1.2 THEORIES OF SCHIZOPHRENIA ....................................................................... 3
1.2.1 Dopamine Theory ............................................................................................. 4
1.2.2 Dopaminergic Animal Models of Schizophrenia ............................................. 6
1.2.3 Glutamate Theory ............................................................................................. 7
1.2.4 Glutamatergic Animal Models.......................................................................... 9
1.2.5 Connection between dopamine and glutamate ............................................... 10
1.3 PREFRONTAL CORTEX..................................................................................... 11
1.3.1 Anatomy of the PFC ....................................................................................... 11
1.3.2 Abnormalities in the PFC................................................................................ 14
1.4 STRIATUM ........................................................................................................... 17
1.4.1 Anatomy of the striatum ................................................................................. 17
1.4.2 Abnormalities in the STR ............................................................................... 18
1.5 ANTIPSYCHOTIC DRUGS ................................................................................ 19
1.5.1 Clinical outcome of antipsychotic drugs......................................................... 19
1.5.2 Mechanism of action....................................................................................... 20
1.6 GSK-3 SIGNALLING .......................................................................................... 21
1.6.1 Regulation of GSK-3 ...................................................................................... 21

vii

1.6.2 Akt-GSK-3 Pathway ........................................................................................ 22
1.6.3 The Wnt Pathway........................................................................................... 25
1.7 GSK-3, AKT AND THE WNT PATHWAY IN SCHIZOPHRENIA ................. 29
1.7.1 GSK-3 and Schizophrenia............................................................................... 29
1.7.2 Akt and Schizophrenia.................................................................................... 29
1.7.3 Wnt and Schizophrenia ................................................................................... 31
1.8 mGLUR2/3 AGONISTS........................................................................................ 32
1.9 OVERVIEW ........................................................................................................... 33
1.10 OBJECTIVES AND RATIONALE .................................................................... 34
1.10.1 Alterations in GSK-3 and Akt signalling induced by the D2DR are
mediated by Dvl-3......................................................................................... 34
1.10.2 The effect of neuropsychiatric drugs and amphetamine on GSK-3 related
signalling....................................................................................................... 35
1.10.3 Regulation of Akt and Wnt signalling by the group II metabotropic
glutamate receptor antagonist LY341495 and agonist LY379268 ............... 36
1.11 REFERENCE LIST ............................................................................................. 38
CHAPTER TWO: Alterations in GSK-3 and Akt signalling induced by the
D2DR are mediated by Dvl-3........................................................ 57
2.1 INTRODUCTION ................................................................................................. 58
2.2 MATERIAL AND METHODS............................................................................. 59
2.2.1 Animal treatment ............................................................................................ 59
2.2.2 Cell culture...................................................................................................... 60
2.2.3 Retroviral infections and transfections ........................................................... 60
2.2.4 PI3-K inhibitor treatments of cell cultures...................................................... 61
2.2.5 Protein isolation and western blotting............................................................. 61
2.2.6 Co-Immunoprecipitations ............................................................................... 62
2.3 RESULTS .............................................................................................................. 63
2.3.1 Regulation of Akt and Wnt pathway proteins by D1DR, D2DR
and D3DR........................................................................................................ 63
2.3.2 The effects of Akt on GSK-3 and β-catenin ................................................... 71
2.3.3 The effects of Dvl-3 on Akt, GSK-3 and β-catenin levels ............................. 74
2.3.4 D2DR association with GSK-3........................................................................ 80
viii

2.4 DISCUSSION ........................................................................................................ 83
2.5 REFERENCES ...................................................................................................... 87
CHAPTER THREE: The effect of neuropsychiatric drugs and amphetamine on
GSK-3 related signalling .......................................................... 92
3.1 INTRODUCTION ................................................................................................. 93
3.2 MATERIAL AND METHODS.............................................................................. 95
3.2.1 Drug Paradigm ................................................................................................ 95
3.2.2 Western blotting.............................................................................................. 96
3.2.3 Co-Immunoprecipitations ............................................................................... 97
3.3 RESULTS .............................................................................................................. 97
3.3.1 Differential effects of haloperidol and clozapine in the PFC and STR .......... 97
3.3.2 The effects of mood stabilizers and antidepressants on Akt and the
Wnt pathway ................................................................................................ 102
3.3.3 The association between the D2DR and GSK-3α/β..................................... 107
3.3.4 The effects of amphetamine on Akt and the Wnt pathway.......................... 110
3.4 DISCUSSION ...................................................................................................... 113
3.5 REFERENCE LIST ............................................................................................. 120
CHAPTER FOUR: Regulation of Akt and Wnt signalling by the group II
metabotropic glutamate receptor antagonist LY341495
and agonist LY379268 ............................................................... 124
4.1 INTRODUCTION ............................................................................................... 125
4.2 MATERIALS AND METHODS......................................................................... 126
4.2.1 Drug Paradigm ............................................................................................... 126
4.2.2 Western blotting............................................................................................ 127
4.2.3 Co-Immunoprecipitations ............................................................................. 127
4.2.4 Locomotor activity........................................................................................ 128
4.3 RESULTS ............................................................................................................ 129
4.3.1 The effects of mGluR2/3 agonism (LY379268) on Akt and Wnt
pathway proteins .......................................................................................... 129
4.3.2 The effects of mGluR2/3 antagonism (LY341495) on Akt and Wnt
pathway proteins .......................................................................................... 134

ix

4.3.3 Interactions between mGluR2/3 and Akt and Wnt pathway proteins........... 134
4.3.4 Effects of LY341495 on locomotion ............................................................ 142
4.4 DISCUSSION ...................................................................................................... 145
4.4.1 mGluR2/3 mediates changes in Wnt and Akt signalling .............................. 145
4.4.2 LY341495 and Behavior............................................................................... 148
4.4.3 Comparison of LY379268 with antipsychotics ............................................ 149
4.5 REFERENCE LIST ............................................................................................. 151
CHAPTER FIVE: GENERAL DISCUSSION.......................................................... 155
5.1 Summary of Results and Conclusions ................................................................ 156
5.1.1 Alterations in GSK-3 and Akt signalling induced by the dopamine D2
receptor are mediated by Dvl-3..................................................................... 156
5.1.2 The effects of neuropsychiatric drugs and amphetamine on GSK- 3
signalling..................................................................................................... 157
5.1.3 Regulation of Akt and Wnt signalling by the group II metabotropic
glutamate receptor antagonist LY341495 and agonist LY379268 ............... 158
5.2 Discussion ............................................................................................................ 158
5.3 Limitations of the Model and future studies ....................................................... 164
5.4 REFERENCE LIST ............................................................................................. 168
APPENDIX A................................................................................................................ 172
CURRICULUM VITA ................................................................................................. 174

x

TABLE OF FIGURES
Figure 1.1: Prefrontal cortex of the human and rat.......................................................... 12
Figure 1.2: The cytoarchitectural features in the PFC of schizophrenia.......................... 15
Figure 1.3: Schematic representation of Akt/GSK3 signalling ....................................... 23
Figure 1.4: Schematic representation of canonical Wnt signalling ................................. 26
Figure 2.1: The effects of D1DR, D2DR and D3DR antagonism on total protein levels
and/or phosphorylation state of Akt and Wnt pathway proteins................... 64
Figure 2.2: The effects of D2DR agonism on total protein levels and/or
phosphorylation state of Akt and Wnt pathway proteins.............................. 67
Figure 2.3: Co-IP experiments showing the association between D2DR and Akt or
GSK-3α/β in drug naïve rats, raclopride or quinpirole treated rats.............. 69
Figure 2.4: The effect of a constitutively active Akt construct or Akt inhibitors,
wortmannin and LY294002 on GSK-3 and β-catenin in SH-SY5Y cells ..... 72
Figure 2.5: The effects of reducing Akt-1 protein levels in vitro and in vivo
on Akt, Dvl-3, GSK-3 and β-catenin using siRNA or transgenic
mice, respectively.. ........................................................................................ 75
Figure 2.6: Changes in Akt, Dvl, GSK-3 and β-catenin following the overexpression
or knockdown of Dvl-3 in SH-SY5Y cells.. .................................................. 78
Figure 2.7: Co-IP experiments examining the association between D2DR and
GSK-3α/β in native SH-SY5Y cells or following viral overexpression
of Dvl-3 or transfection with a constitutively active Akt construct............... 81
Figure 3.1: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the PFC of rats treated with haloperidol
or clozapine................................................................................................... 98
Figure 3.2: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the STR of rats treated with haloperidol
or clozapine................................................................................................. 100
Figure 3.3: Changes in the total protein levels and/or phosphorylation state
of Wnt pathway proteins and Akt in the PFC and STR of rats treated
with lithium or valproic acid........................................................................ 103

xi

Figure 3.4: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the STR of rats treated with fluoxetine or
imipramine.. ............................................................................................... 105
Figure 3.5: Co-IP experiments showing the association between D2DR and Akt,
GSK-3 and/or Dvl-3 in the PFC of haloperidol, clozapine, lithium
and valproic acid treated rats ...................................................................... 108
Figure 3.6: Changes in the total protein levels and/or phosphorylation state of
Wnt pathway proteins and Akt in the PFC and STR of rats treated
with amphetamine....................................................................................... 111
Figure 3.7: Co-IP experiments showing the association of between D2DR and Akt
and GSK-3 in the PFC of rats treated with amphetamine............................ 114
Figure 4.1: The effects of repeated administration of LY379268 on Wnt pathway
proteins and Akt........................................................................................... 130
Figure 4.2: The effects of acute administration of LY379268 on Wnt pathway
proteins and Akt.......................................................................................... 132
Figure 4.3: The effects of repeated administration of LY341495 on Wnt pathway
proteins and Akt.......................................................................................... 135
Figure 4.4: The effects of acute administration of LY341495 on Wnt pathway
proteins and Akt.......................................................................................... 137
Figure 4.5: Co-Immunoprecipitation experiments showing association between
mGluR2/3 and Wnt pathway proteins and/or Akt in drug naïve rats or
following LY379268 treatment................................................................... 140
Figure 4.6: Total horizontal locomotor activity for rats treated acutely or repeatedly
with LY341495 or LY341495 and SB216763............................................ 143
Figure 5.1: Working model of antipsychotics and mGluR2/3 agonist regulation of
Akt and Wnt signalling ................................................................................ 160

xii

LIST OF APPENDICES

APPENDIX A: UWO Council of Animal Care - Animal Protocol Approval................ 170

xiii

LIST OF ABBREVIATIONS
ACd - dorsal anterior cingulated cortex
ACv - ventral anterior cingulated cortex
AId - dorsal agranular insular cortex
AIv - ventral agranular insular cortex
APC - adenomatous polyposis coli
CCAC - Canadian Council on Animal Care
Co-IP - co-immunoprecipitation
COMT - catechol-O-methyl transferase
D1DR - dopamine D1 receptor
D2DR - dopamine D2 receptor
D3DR - dopamine D3 receptor
D4DR - dopamine D4 receptor
D5DR - dopamine D5 receptor
DA - dopamine
DAT - dopamine transporter
DAT-KO - dopamine transporter knockout mice
DISC1 - Disrupted-in-schizophrenia 1
DKK - Dickkopf
DMEM - Dulbecco's Modified Eagle Medium
DSM-IV - Diagnostic and Statistical Manual of Mental Disorders volume IV
Dvl - dishevelled
EPS - extrapyramidal symptoms

xiv

FBS - fetal bovine serum
FR2 - frontal area 2
FST - force swim test
Fz - Frizzled receptor
GABA - γ-aminobutyric acid
GPCR - G-protein coupled receptor
GSK-3 - glycogen synthase kinase-3
HZ - heterozygous
i.m. - intermuscular
IL - infralimbic cortex
IP - immunoprecipitation
KO - knockout
LEF - lymphoid enhancer factor
LO - lateral orbital cortex
LRP5/6 - low-density lipoprotein receptor-related protein 5/6
mGluR - metabotropic glutamate receptor
MAPK - mitogen-activated protein kinase
MO - medial orbital cortex
mTOR - mammalian target of rapamycin
NMDA - N-methyl d-asparate
p - phosphorylated
PCP - phencyclidine
PCP Pathway - planar cell polarity pathway

xv

PDK1 - 3-phosphoinositol-dependent kinase1
PFC - prefrontal cortex
PI3-K - phosphoinositide 3-kinase
PIP2 - phosphatidylinositol-4,5-biphosphate
PIP3 - phosphatidylinositol-3, 4, 5-triphosphate
PKA - protein kinase A
PKB - protein kinase B
PKC - protein kinase C
PL - prelimbic cortex
PP2A - protein phosphatase 2
PPI - prepulse inhibition
RGS4 - regulator of G-protein signalling 4
s.c. - subcutaneous
Ser - serine
SNAP-25 - synaptosomal-associated protein 25
STR - striatum
TCF - T-cell factor
Thr - Threonine
VTA - ventral tegmental area
WB - western blotting
WM – white matter
WT - wild type

xvi

1

CHAPTER ONE
INTRODUCTION
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1.1 SCHIZOPHRENIA
1.1.1 Epidemiology and clinical description of schizophrenia
Schizophrenia is a chronic debilitating mental disorder afflicting 1% of the
population worldwide1. The incidence rate of schizophrenia is similar throughout the
world and independent of race, gender and social status1, 2. Schizophrenia tends to
emerge during late adolescence or early adulthood and usually persists throughout life3.
There are currently no biological markers for schizophrenia and diagnosis relies on the
presentation of clinical symptoms as defined by the Diagnostic and Statistical Manual of
Mental Disorders volume IV (DSM-IV). According to the DSM-IV, schizophrenia is
characterized by three broad symptom clusters; positive symptoms, negative symptoms
and cognitive impairments. Positive symptoms are behaviours apparent in schizophrenia
patients but are absent in healthy unaffected individuals and include hallucinations and
delusions.

Negative symptoms are deficit states in which basic emotional and

behavioural processes are diminished or absent. Negative symptoms include blunted
affect, anhedonia (lack of pleasure), avolition (lack of motivation) or social withdrawal.
Cognitive impairments include deficits in attention, memory, learning and executive
functioning.
Given the diversity of symptoms, schizophrenia impacts almost every aspect of
life, ranging from difficulties in obtaining and holding competitive full-time employment
to meeting basic living needs. Thus, there is a substantial financial burden associated
with caring for patients with schizophrenia (i.e. health care cost, lost of productivity etc.).
In 1996, it was reported that the estimated total financial burden for schizophrenia in
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Canada was $3 billion dollars4. Therefore, improving functioning remains the critical
challenge for the management of schizophrenia.

1.1.2 Etiology of Schizophrenia
Schizophrenia is a complex illness and both genetic and environmental factors
play a role in the etiology of schizophrenia. Rates of schizophrenia are higher among
relatives of patients than in the general population suggesting there is a heritable
component to schizophrenia5. Genetic risk increases with each affected relative, reaching
nearly 50% when both parents are affected6 and 70% when a monozygotic twin is
affected7, 8.

However, a single gene is not responsible for schizophrenia and

schizophrenia does not follow a single gene inheritance pattern. Rather, several genes or
clusters of genes contribute to the genetic vulnerability of an individual9. In addition,
some environmental factors, have been identified that can contribute to an increased risk
of schizophrenia10. For example, prenatal exposure to the influenza virus, low prenatal
vitamin D, obstetrical complications (hypoxia/ischemia), exposure to adverse intrauterine
events, cannabis use and repeated psychological stress have been identified as risk factors
for the development of schizophrenia11-17.

1.2 THEORIES OF SCHIZOPHRENIA
Although the etiology of schizophrenia is unknown, there are numerous theories
that have been proposed to explain the cause and progression of schizophrenia.
However, based on biological evidence, the dopamine (DA) and glutamate theories of
schizophrenia remain the most dominant theories.

4
1.2.1 Dopamine Theory
Dopamine
DA is the predominant catecholamine neurotransmitter in the mammalian brain,
where it regulates a variety of functions including locomotor activity, cognition, emotion
and endocrine function18. At the cellular level, two classes of 7-transmembrane receptors
that couple to heterotrimeric G binding proteins mediate the various physiological
functions regulated by DA. The D1-class DA receptors are composed of D1DR and
D5DR and are mostly coupled to Gsα, whereas D2-class DA receptors, D2DR, D3DR and
D4DR are coupled to Gi/Go18. DA receptors regulate a variety of signalling pathways,
including protein kinase A (PKA), protein kinase C (PKC), mitogen-activated protein
kinase (MAPK) and calcium channels.
There are four major dopaminergic pathways in the brain: mesolimbic,
mesocortical, nigrostriatal and tuberoinfundibular pathways.

The mesolimbic and

mesocortical pathways have been associated with the positive and negative symptoms of
schizophrenia. Dopaminergic neurons of the mesolimbic system originate in the ventral
tegmental area (VTA) and project to the components of the limbic system such as the
nucleus accumbens, amygdala, hippocampus and the medial prefrontal cortex.

The

mesocortical dopaminergic system also originates in the VTA and project to the frontal
cortex, in particular to the prefrontal cortex.

Dopamine hypothesis
The DA hypothesis proposes that symptoms of schizophrenia are due to abnormal
dopaminergic functioning19.

The hypothesis originated with the discovery that all
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antipsychotics, drugs used for the treatment of schizophrenia, are D2DR antagonists20-22.
Reserpine, a drug that leads to the depletion of DA from the synapse was also found to be
effective for treating psychosis23. Further evidence was provided by studies using
amphetamine, an indirect DA agonist, showing that amphetamine induces psychotic
symptoms indistinguishable from the positive symptoms of schizophrenia in otherwise
normal humans24. Furthermore, use of amphetamine by schizophrenia patients often
causes a relapse of psychosis and/or exacerbates the positive symptoms25. Numerous
studies have also investigated DA functioning in patients with schizophrenia and elevated
presynaptic striatal DA has been consistently reported26-28. Meta-analyses have shown
there is a slight elevation in striatal D2DR/D3DR density in schizophrenic patients
independent of the effects of antipsychotic drugs29-31. However, it has been suggested
that a change in the functional state of the D2DR may be more important for the
symptoms of schizophrenia than changes in receptor density32. Recent studies have
shown that the D2DR can exist in a state of low (D2low) or high (D2high) affinity for DA,
with D2high being the active state33, 34. Patients with schizophrenia are supersensitive to
dopamine24, 35, which correlates with elevated levels of D2 receptors in the D2high state36.
Given the importance of DA and D2DR in schizophrenia and antipsychotic drug
action, numerous genetic studies have investigated elements of the dopamine system,
including the DA transporter (DAT) and DA receptors, as possible susceptibility genes.
Several studies have shown that DAT gene variants do not contribute to the etiology of
schizophrenia37-39. This finding is consistent with imaging studies that show a normal
distribution of DAT in the striatum40,

41

. Data for the D2DR is conflicting but there

appears to be no strong association between D2DR gene variants and schizophrenia42, 43.
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Studies involving other dopamine receptors have also been conducted but do not appear
to be associated with schizophrenia44-47. Given the lack of association between dopamine
receptors and schizophrenia, studies have now begun to explore abnormalities in
dopaminergic intracellular signalling pathways. Genetic studies have identified genes
involved in dopaminergic pathways such as Akt-148-53, disrupted-in-schizophrenia 1
(DISC1)54, catechol-O-methyl transferase (COMT)55-58 and regulator of G-protein
signalling 4 (RGS4)59-62 as possible susceptibility genes for schizophrenia.

1.2.2 Dopaminergic Animal Models of Schizophrenia
Based upon the dopamine theory of schizophrenia several hyperdopaminergic
animal models have been developed including the amphetamine-sensitization model and
the dopamine transporter knockout (DAT-KO) mouse. The amphetamine-sensitization
model is a well-established hyperdopaminergic animal model of schizophrenia63.
Amphetamine-sensitization is the consequence of repeated exposure to amphetamine,
resulting in enhanced neurochemical and behavioural responses to a subsequent
amphetamine challenge. More importantly, amphetamine-sensitization shares several
key neurochemical and behavioural similarities to schizophrenia64.

For example,

amphetamine treated rats show increased striatal dopamine release and have heightened
displacement of raclopride binding to D2DR following an amphetamine challenge,
suggesting that a greater portion of D2DR are occupied by DA65,

66

. Amphetamine-

sensitization leads to dopamine supersensitivity and increase in D2high receptors67. In
addition, amphetamine-sensitized animals exhibit hyperlocomotor activity, a behaviour
representative of the positive symptoms of schizophrenia in humans66, 68, 69. In addition,
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reductions in prepulse inhibition (PPI) are observed in amphetamine-sensitized animals66,
68, 69

. PPI is a phenomenon whereby a weaker prestimulus attenuates a subsequent

startling stimulus and is a measure of sensorimotor gating70.

Deficits in PPI and

sensorimotor gating have been reported in patients with schizophrenia70-72. Treatment
with antipsychotic drugs attenuates hyperlocomotor activity and reverses the deficits in
PPI in amphetamine-sensitized rats69, 73. Thus, the amphetamine-sensitization model also
has predictive validity for antipsychotic efficacy. In addition, amphetamine sensitized
rats show impairments in tasks that require sustained attention such as the operant signal
detection task74 and the 5 choice serial reaction time task75, consistent with the attention
deficits observed in schizophrenic patients. However, it appears working memory and
long-term memory are not affected by amphetamine sensitization, even though
impairments in memory are observed in patients with schizophrenia76,

77

. Therefore,

amphetamine sensitization does not model all aspects of schizophrenia but is a good
model for investigating the positive symptoms of schizophrenia.

1.2.3 Glutamate Theory
Glutamate Receptors
L-glutamate is the major excitatory neurotransmitter in the mammalian central
nervous system binding to both ligand-gated ion channels and G-protein coupled
receptors (GPCR)78. N-methyl d-asparate (NMDA) receptors are heteromeric ionotropic
glutamate receptors composed of a NR1 subunit in combination with NR2 and/or NR3
subunits. There are eight different NR1 subunits generated by alternative splicing, four
NR2 subunits (A, B, C and D) and two NR3 subunits (A and B). NMDA receptors
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permit the movement of calcium across the post-synaptic membrane, thereby activating
second messenger systems. Metabotropic glutamate receptors (mGluR) are GPCR and
are divided into 3 groups based on sequence, pharmacology and G-protein coupling:
Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3) and Group III
(mGluR4, mGluR6, mGluR7 and mGluR8)79. MGluR can regulate several different
signalling pathways, including PKA and MAPK.

Glutamate theory
The

glutamate

theory

postulates

that

abnormalities

in

glutamatergic

neurotransmission are responsible for the symptoms of schizophrenia80. The glutamate
hypothesis of schizophrenia originated with the clinical observation that phencyclidine
(PCP) and ketamine, non-competitive NMDA receptor antagonists, induce schizophrenialike psychosis, emotional blunting and working memory disturbances in humans81-84.
Furthermore, PCP can exacerbate psychosis and cognitive impairments in patients with
schizophrenia85-87.

Genetic studies have investigated NMDA subunits as possible

susceptibility genes for schizophrenia and have implicated NR2A (GRIN2A) and NR2B
(GRIN2B) as candidate genes for schizophrenia88, 89. Postmortem studies have revealed
regional and subunit specific alterations in the expression of NMDA receptor subunits.
For example, increases in the NR2A subunit were found in the occipital cortex90, whereas
no change in expression was found in the hippocampus or thalamus of schizophrenic
patients91. For NR2B, increases in the mRNA levels were reported in the hippocampus
and thalamus92, 93 but not in the prefrontal or occipital cortex of schizophrenic patients90.
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In addition to NMDA, evidence implicating mGluR in schizophrenia has
emerged.

For example, mGlu3R and mGlu5R have been identified as possible

schizophrenia susceptibility genes94-96.

However, there appears to be no significant

change in the expression of mGluR5 mRNA in the prefrontal cortex, hippocampus or
striatum of schizophrenic patients97-99. Several post-mortem studies in schizophrenic
patients have also reported no significant changes in mGluR3 mRNA and protein levels
or in the immunoreactivity of mGluR2/398, 100-102. However, a decrease in the dimer form
of mGluR3 has been reported in the prefrontal cortex of schizophrenic patients103.
Furthermore, it has been shown that mGluR2/3 agonists have antipsychotic-like
properties. The mGluR2/3 agonist, LY354740 normalized cognitive deficits induced by
ketamine in humans104.

A preclinical study has shown that the mGluR2/3 agonist,

LY2140023 (prodrug of LY404039) led to improvements in both positive and negative
symptoms of schizophrenia compared to placebo105.

1.2.4 Glutamatergic Animal Models
Based upon the schizophrenic-like symptoms NMDA receptor antagonists induce
in humans, PCP and ketamine animal models have been developed. The PCP model is
the most well-studied and accepted glutamatergic animal model of schizophrenia106. It
has been shown that PCP treated rats exhibit hyperlocomotion and deficits in PPI107, 108
and that a variety of different antipsychotics can attenuate these behaviours109. PCP
treated rats also exhibit deficits in social interaction110, 111 and impairments in working
memory76. Overall, PCP treated rats are thought to model various negative symptoms
and cognitive deficits, as well as the positive symptoms of schizophrenia. However,
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targeting NMDA receptors for pharmaceutical purposes is problematic. Attempts to
develop therapeutic agents directed at NMDA receptors have been unsuccessful due to
adverse effects including memory impairments and neurotoxicity112, 113. A more gentle
approach was to target the glycine modulation site on the NMDA receptor. Glycine is a
co-agonist necessary for NMDA receptor activation. However, clinical trials of glycine or
glycine derivatives failed to consistently demonstrate therapeutic benefits114-116.
Animal models targeting the mGluR2/3 have also been created, given recent
findings concerning mGlu3R in schizophrenia. Although data is still limited, treatment
with mGluR2/3 antagonists, LY341495 or LY366457 causes increases in locomotor
activity that can be attenuated by mGluR2/3 agonists and antipsychotic drugs115.
However, unlike amphetamine, increases in locomotor activity are thought to be due to
impairments in habituation117,

118

, a process that is impaired in patients with

schizophrenia119. Thus, targeting mGluR2/3 may provide valuable information about the
role of mGluR2/3 in the manifestation of symptoms associated with schizophrenia.

1.2.5 Connection between dopamine and glutamate
Although, most descriptions of the dopamine and glutamate theories of
schizophrenia centre solely around DA or glutamate respectively, it is important to note
that these neurotransmitter systems are in fact extensively interconnected. Both the DA
and glutamate systems interact in several brain regions relevant to schizophrenia,
including the prefrontal cortex (PFC), midbrain and striatum120 and work together to
regulate normal cortical activity related to perception and cognition121, 122. In the PFC,
different types of DA and glutamate receptors are localized on the pyramidal neurons and
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dopaminergic neurons from the VTA project to the glutamate-containing pyramidal cells
in the PFC. Activation of DA receptors in the PFC are known to modulate glutamatergic
neuronal activity by providing either an inhibitory123,

124

or excitatory125 input to

pyramidal neurons. More specifically, activation of D2DR has been reported to inhibit
pyramidal cells124, while activation of D1DR has been shown to excite pyramidal cells126.
Thus, it is important to keep in mind when discussing either the DA or glutamate theories
of schizophrenia, that one neurotransmitter system directly affects the other.

1.3 PREFRONTAL CORTEX
1.3.1 Anatomy of the PFC
The prefrontal cortex (PFC) is involved in several higher brain functions, such as
perception, attention, and memory127. The PFC is the association cortex of the frontal
lobe and is located anterior to the motor and premotor regions. The anatomical boundary
of the PFC is not easily delineated but is defined by its connectivity with the mediodorsal
nucleus of the thalamus127. According to the cytoarchitectonic map of Brodmann it
consists of areas 8-13, 24, 32, 46 and 47 (Figure 1.1a). Cortical neurons of the PFC are
arranged in 6 layers, numbering from the pial surface of the cortex to the underlying
white matter.

Distributed across these layers are different types of glutamatergic

pyramidal cells representing ~75% of the cortex. The remaining ~25% of neurons are
interneurons and utilize the neurotransmitter γ‐aminobutyric acid (GABA).
Anatomical and functional characteristics have been used to identify the PFC in
different species. The PFC circuitry in rats, primates and humans share a number of
connections, including connections with the thalamus (i.e. mediodorsal nucleus), VTA,
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Figure 1.1: Prefrontal cortex of the human and rat.
A) Lateral, medial and orbital view of the human prefrontal cortex are numbered
according to the Brodmann’s cytoarchitectonic map. (Adapted from Fuster et al.,
1997)
B) Medial views of the rat prefrontal cortex composed of the frontal area 2 (FR2), dorsal
and ventral anterior cingulated cortices (ACd and ACv, respectively), prelimbic
cortex (PL) and the infralimbic cortex (IL), medial orbital cortex (MO) dorsal and
ventral agranular insular cortices (AId and AIv, respectively) and the lateral orbital
cortex (LO). (Adapted from Uylings et al., 1990).
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A) Human PFC

B) Rat PFC
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basal ganglia and with other cortices128. In the rat, the PFC is composed of the medial
and lateral PFC (Figure 1.1b)128. The medial PFC includes frontal area 2 (FR2), dorsal
and ventral anterior cingulate cortices (ACd and ACv, respectively), prelimbic cortex
(PL) and the infralimbic cortex (IL) and medial orbital cortex (MO). The lateral PFC is
composed of the dorsal and ventral agranular insular cortices (AId and AIv, respectively)
and the lateral orbital cortex (LO).
The PFC receives both dopaminergic and glutamatergic afferents.

The PFC

receives dopaminergic projections from the VTA, whereas glutamatergic afferents from
the thalamus and hippocampus also project to the pyramidal neurons.

Reciprocal

glutamategic projections from the pyramidal neurons project onto the thalamus and
hippocampus. The striatum also receives glutamatergic projections from the PFC.

1.3.2 Abnormalities in the PFC
The PFC is a site of abnormal functioning in schizophrenia129 and is also
implicated in the action of antipsychotic drugs130. Reduced blood flow in the PFC of
schizophrenia patients, particularly during working memory tasks has been consistently
reported131-133. Several abnormalities in the cytoarchitecture of the PFC in schizophrenic
patients have also been described (Figure 1.2). Postmortem studies of the PFC show
smaller somal size of pyramidal cells, reduced neuropil and an increase in neuronal
density but no change in the cell number134. It has also been found that pyramidal
neurons, particular in layers II and III have shorter basilar dendrites, lower dendritic spine
density and a reduced axonal arbor in schizophrenia135-139. Reduction in the expression of
presynaptic markers, including synaptophysin, complexin I and synaptosomal-associated
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Figure 1.2: The cytoarchitectural features in the PFC of schizophrenia.
Schematic cartoon of the cytoarchitectural features in the PFC of schizophrenia. There is
no change in the number of pyramidal neurons but the pyramidal neurons are smaller and
are densely packed. The reduced neuronal size and increase in neuronal density
correlates with a reduced neurophil. The cortex is thinner, especially in laminae II and
III. There are abnormalities in the axonal (green) and dendritic (red) arborization.
Pyramidal neurons have shorter dendritic spines and lower spine density and a reduced
axonal arbor.
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protein 25 (SNAP-25) in the PFC have been reported140-142.

Abnormalities in the

constituents of pre- and postsynaptic markers are also suggestive of impairments in PFC
connectivity.

Changes in the PFC are not the only finding in schizophrenia,

abnormalities have also been found in areas that are anatomically connected to the PFC,
including the thalamus, striatum and hippocampus143. For example, postmortem studies
revealed a reduction in cell number in the mediodorsal thalamic nucleus, the principle
source of thalamic projections to the PFC144. Overall, abnormalities found in the PFC
and the general function of the PFC indicates the importance of this brain region in
studying schizophrenia.

1.4 STRIATUM
1.4.1

Anatomy of the striatum

The striatum (STR) is involved in motor, cognitive and emotional behaviours. The
STR is composed of the caudate and putamen and is the primary input structure of the
basal ganglia. The principle neuronal cell type of the STR is the GABAergic medium
spiny projection neuron accounting for 90-95% of the neuronal population. Interneurons
make up the remaining population of neurons. Interneurons have been identified as large
aspiny neurons that utilize the neurotransmitter acetylcholine or medium aspiny neurons,
which include neurons that contain somatostatin, neuropeptide Y or calcium-binding
protein parvalbumin.
The STR receives both glutamatergic and dopaminergic projections.

The

glutamatergic inputs arise from all over the cerebral cortex and are topographically
organized, with sensory and motor cortices projecting to the putamen and associative
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cortex projecting to the caudate and rostral putamen. In addition, the STR receives
glutamatergic projections from the amygdala and thalamus. The STR also receives
dopaminergic input from the substantia nigra pars compacta (SNc). Projections from the
STR participate in both the “direct” and “indirect” pathways of the basal ganglia. In the
direct pathway the STR sends projections to the substantia nigra pars reticulata and
globus pallidus internal segment, which in turn sends projections to the thalamus. In the
indirect pathway, projections from the STR are received by the globus pallidus external
segment, which sends projections to the subthalamic nucleus and in turn projects to the
globus pallidus internal segment. The globus pallidus internal segments send projections
to the thalamus. The thalamus in these circuitries projects back onto the cortex and it is
the balance of these opposing pathways that regulates the cortical activity.

1.4.2 Abnormalities in the STR
Several studies have shown alterations in striatal synaptic contacts in
schizophrenia. Smaller spines and an increase in the volume of postsynaptic densities
have been reported145, 146. In addition, differences in synaptic types have been observed,
such as fewer symmetrical synapses in striatal tissue of schizophrenia patients have been
documented147. The STR has often been examined for antipsychotic effects and in
animal models of schizophrenia. The STR has an abundance of DA terminals and D2DR
and as such this region has been the focus of several studies involving the dopaminergic
animal models amphetamine-sensitization and DAT-KO mice63,

148

.

In addition,

numerous antipsychotic drugs studies have also focused on the STR, as antipsychotic
drugs are D2DR antagonists149, 150.
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1.5 ANTIPSYCHOTIC DRUGS
1.5.1 Clinical outcome of antipsychotic drugs
Antipsychotic drugs alleviate the positive symptoms of schizophrenia but have no
or a limited effect on the negative or cognitive symptoms of the disease151, 152. There are
serious side effects associated with antipsychotic treatment, including sedation,
cardiovascular complications, seizures and weight gain which can lead to type ΙΙ
diabetes153.

Other common side-effects, collectively referred to as extrapyramidal

symptoms (EPS), include parkinsonism and tardive dyskinesia. Side effects are often
serious and represent the main reason why patients stop treatment153.
Patients with schizophrenia show a wide-range of outcomes when treated with
antipsychotics. It is estimated that 12-30% of all patients with schizophrenia do not
respond adequately to antipsychotic treatments and are classified as treatment-resistant154.
Treatment-resistant is defined as having tried at least three different antipsychotic
mediations for a 6-8 week period of time with persistent positive symptoms155. Another
problem is that patients can become unresponsive to antipsychotic medication resulting in
a relapse of a psychotic episode156. It is estimated that following a relapse, one in six
patients will fail to achieve remission and experience psychotic episodes157. Given the
issues of side-effects, treatment-resistance and unresponsiveness to antipsychotics, there
is a clear need to find more effective and safer treatment options for schizophrenia.
Antipsychotic drugs are categorized as either typical (first generation) or atypical
(second generation) based on their binding profiles. In general, typical antipsychotics
have a higher binding affinity than atypical antipsychotics for the D2DR158 and most
atypical antipsychotics also bind to serotonin 5-HT2 receptors159,

160

. Initially, it was
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thought that atypical antipsychotics (i.e. clozapine, risperidone) would alleviate psychosis
and improve negative symptoms and cognitive impairments, making them superior to
typical antipsychotics (i.e. haloperidol). However, it has been shown that atypicals have
a comparable efficacy to typicals when it comes to alleviating psychosis and also have a
limited effect on negative symptoms and cognitive impairments152. The main difference
between these classes of drugs is their side-effect profiles. Atypicals cause less EPS than
typicals, whereas atypicals induce metabolic side effects (weight gain, increased
triglycerides and cholesterol)152, 161.

1.5.2 Mechanism of action
Although the binding profiles of antipsychotic drugs differ, they all antagonize
D2DR20-22 and D2DR antagonism is essential for the alleviation of psychosis162.
However, beyond the blockade of the D2DR, the molecular mechanism responsible for
the therapeutic effects of antipsychotic drugs remains elusive.

There are several

intracellular signalling pathways known to be regulated by the D2DR including protein
kinase C (PKC), protein kinase A (PKA) and mitogen-activated protein kinase
(MAPK)163. However, there is currently no persuasive evidence linking PKC, PKA or
MAPK to schizophrenia or antipsychotic drug action164-166. Recently, it has been shown
that the D2DR regulates glycogen synthase kinase-3 (GSK-3)167. Furthermore, a variety
of different antipsychotics can effect GSK-3150 and GSK-3 has been implicated in
schizophrenia168.
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1.6 GSK-3 SIGNALLING
1.6.1 Regulation of GSK-3
GSK-3 is a ubiquitously expressed serine/threonine protein kinase. There are two
isoforms of GSK-3 that are encoded by different genes; GSK-3α and GSK-3β169. These
two isoforms are structurally similar (84% homology) except for an additional glycinerich extension on the N terminus of GSK-3α170. GSK-3 has over 40 putative substrates
that are generally divided into metabolic proteins, signalling proteins, structural proteins
and transcription factors171. GSK-3 is involved in numerous signalling cascades and is
regulated by distinct mechanisms to avoid indiscriminate phosphorylation of its many
substrates.

Mechanisms responsible for regulating GSK-3 include phosphorylation,

binding with protein complexes and sub-cellular localization. With respect to
phosphorylation, GSK-3 is constitutively active and its activity is inhibited by
phosphorylation on serine residues (Ser9 of GSK-3β; Ser21 of GSK-3α)172. GSK-3 is
also autophosphorylated on tyrosine residues (Y216 of GSK-3α; Y279 of GSK-3β)
resulting in an increase in kinase activity173. The ability of GSK-3 to phosphorylate
select substrates is also regulated by the protein complexes it forms. For example, GSK3 in complex with the scaffolding proteins Axin and adenomatous polyposis coli (APC)
enables GSK-3 to phosphorylate the substrate, β-catenin174. If this complex is disrupted,
GSK-3 is unable to phosphorylate β-catenin. Lastly, the sub-cellular localization of
GSK-3 regulates the availability of potential substrates.

GSK-3 is located in the

cytoplasm, plasma membrane and nuclear fractions of a cell175. Activation of particular
GSK-3 signalling pathway can result in the translocation of GSK-3 within the cell. For
example, activation of the Wnt pathway translocates GSK-3 from the cytoplasm to the
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plasma membrane175. This change in the sub-cellular localization of GSK-3 determines
what substrates are available to GSK-3.
Although GSK-3 is involved in several important signalling pathways,
participation in the Wnt and Akt signalling cascades is of particular interest, given that
these pathways have been implicated in schizophrenia and antipsychotic drug action176.

1.6.2 Akt-GSK-3 Pathway
Akt, also known as protein kinase B (PKB) is a serine/threonine protein kinase.
There are 3 isoforms of Akt denoted Akt-1, Akt-2 and Akt-3. Akt-1 is ubiquitously
expressed. Akt-2 is predominantly expressed in insulin target tissues and Akt-3 is the
predominant isoform in the brain.
All three isoforms of Akt are regulated by phosphorylation on Thr308 and Ser473
residues and phosphorylation of these sites results in increased kinase activity. Figure 1.3
depicts the Akt-GSK-3 pathway. Akt is activated in a phosphoinositide 3-kinase (PI3-K)
dependent manner through the generation of membrane bound phosphatidylinositol-3, 4,
5-triphosphate (PIP3). Akt binds to PIP3 and is then phosphorylated on Thr308 by 3phosphoinositol-dependent kinase1 (PDK1)177, 178 and on Ser473 by mammalian target of
rapamycin complex (mTORc)179. Akt then phosphorylates GSK-3α/β on its serine
residues, inhibiting GSK-3 activity172.
Recently, it has been shown that dopamine can regulate Akt activity.
Administration of apomorphine (non-selective dopamine agonist) or amphetamine
decreases phosphorylated Akt and consequently results in a decrease in phosphorylated
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Figure 1.3: Schematic representation of Akt-GSK-3 signalling.
Akt is activated in response to phosphoinositide 3-kinase (PI3-K) mediated signalling.
PI3-K is phosphorylated and subsequently activated by tyrosine kinase receptors. PI3-K
phosphorylates
phosphatidylinositol-4,5-biphosphate
(PIP2)
generating
phosphatidylinositol-3,4,5 triphosphate (PIP3). Akt is recruited to the plasma membrane
by binding to the docking protein PIP3 and is phosphorylated on two critical residues
Thr308 and Ser473. Akt is phosphorylated on the Thr308 by 3-phosphoinositoldependent kinase (PDK1) and on the Ser473 by mammalian target of rapamycin complex
(mTORc). Activated Akt phosphorylates GSK-3.
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GSK-3 in the striatum of rats148, 180. The dopamine transporter knockout (DAT-KO) mice
exhibit a increase in striatal DA levels resulting in a decrease in phosphorylated Akt and
GSK-3 levels148,

180

. Furthermore, D2DR and D3DR knockout mice show increased

phosphorylation of Akt and GSK-3 but this change was not observed in D1DR knockout
mice or mice treated with an antagonist for the D4DR167. Thus, Akt-GSK-3 signalling is
regulated by dopamine and more specifically D2DR and D3DR.

1.6.3 The Wnt Pathway
Wnt proteins are secreted glycoproteins that bind to Frizzled (Fz) receptors and
the co-receptor low-density lipoprotein receptor-related protein 5/6 (LRP5/6). This event
can activate one or more of the 3 distinct branches of the Wnt pathway: (1) the Wnt/Ca2+
pathway, (2) the planar cell polarity (PCP) pathway and/or (3) the canonical Wnt
pathway.

The precise combination of Wnt ligands (19 mammalian members), Fz

receptors (10 mammalian members) and the LRP5/6 determines which branch is
activated in a manner that is currently not well understood181. The Wnt/Ca2+ pathway
results in the elevation of intracellular Ca2+ levels and subsequent activation of calciumdependent kinases and phosphatases182. The PCP pathway involves the JNK cascade and
serves to regulate the actin cytoskeleton183. The canonical Wnt pathway involves the
regulation of GSK-3 and it is the canonical Wnt pathway that has been implicated in
schizophrenia and antipsychotic drug action.
For simplicity the canonical Wnt pathway will be referred to as the Wnt pathway
throughout the remainder of the thesis. Figure 1.4 depicts the Wnt pathway in its resting
state and upon activation. Briefly, when the Wnt pathway is not stimulated (resting state)
GSK-3 forms a phosphorylation complex with the cytoplasmic proteins Axin and
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Figure 1.4: Schematic representation of canonical Wnt signalling
a) Resting State: Under non-stimulated conditions, glycogen synthase kinase-3
(GSK-3), Axin and adenomatous polyposis coli (APC) forms the
“phosphorylation complex” facilitating the phosphorylation of β-catenin by GSK3. Phosphorylated β-catenin is targeted for ubiquitin-mediated degradation by a
proteasome.
b) Activation of the canonical Wnt pathway: The binding of a Wnt ligand to its
cognate frizzled receptor (Fz) and low-density lipoprotein receptor-related protein
5/6 (LRP) activates the transducer protein, dishevelled (Dvl). Dvl is recruited to
the Fz receptor and self-associates to form a long chain of Dvl proteins referred to
as a Dvl polymer. Activation of Dvl leads to the distribution of the
“phosphorylation complex”, allowing for the stabilization of
β-catenin.
Unphosphorylated β-catenin accumulates in the cytoplasm and then translocates
to the nucleus where it associates with T-cell factor/lymphocyte enhancer factor
(TCF/LEF) to mediate transcription.
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APC174, 184. When complexed with Axin and APC, GSK-3 is able to phosphorylate the
transcription factor, β-catenin. Phosphorylation of β-catenin targets it for ubiquitylated
degradation by the proteasome185. Binding of a Wnt ligand to its cognate Fz receptor and
LRP activates the Wnt pathway leading to phosphorylation of the signal transducer
protein, dishevelled (Dvl).

Dvl inhibits GSK-3 by disrupting the GSK-3/Axin/APC

phosphorylation complex resulting in the stabilization of β-catenin186, 187. Subsequently,
β-catenin translocates to the nucleus, where it interacts with the transcription factors, Tcell factor/lymphoid enhancer factor (TCF/LEF) to regulate the expression of target
genes188, 189.
There are three mammalian isoforms of Dvl denoted Dvl-1, Dvl-2 and Dvl-3. All
three isoforms are expressed in the brain and all three isoforms regulate GSK-3. The
exact mechanism concerning how Dvl interferes with the phosphorylation complex is
poorly understood but Dvl possesses three highly conserved binding domains (DIX, DEP
and PDZ) allowing for interactions with diverse proteins, including kinases, phophatases
and adaptor proteins190, 191. Upon activation, Dvl is recruited to the plasma membrane192,
which allows Dvl to self-associate via its DIX domain forming a long Dvl polymer
chain193. These Dvl polymers serve as scaffolds for the recruitment of other proteins and
is necessary for further signalling193. It is known that upon activation, Dvl recruits Axin
and GSK-3 to the plasma membrane175. It is thought that this series of events lead to the
inhibition of GSK-3 and ultimately results in the stabilization of β-catenin.
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1.7 GSK-3, AKT AND THE WNT PATHWAY IN SCHIZOPHRENIA
1.7.1 GSK-3 and Schizophrenia
Post-mortem studies have found a decrease in GSK-3β mRNA and protein levels
in the frontal cortex of schizophrenic patients168, 194. In a separate study, reductions in
phosphorylated GSK-3β in the frontal cortex were noted but no change in total GSK-3β
protein levels were reported49.

GSK-3β has also been identified as a possible

schizophrenia susceptibility gene195, 196. Although most studies have focused on GSK-3β,
reductions in GSK-3α in lymphocytes of schizophrenic patients have also been found197.
Partial animal models of schizophrenia have also supported the involvement of GSK-3 in
schizophrenia. Reductions in phosphorylated GSK-3 levels have been reported in several
animal models, including the amphetamine, DAT-KO mouse, PCP and ventral
hippocampal lesion models148,

198-200

. Furthermore, administration of GSK-3 inhibitors

normalized spontaneous hyperlocomotion in DAT-KO mice148, a behavioural measure
that correlates to positive symptoms.

Other animal studies have demonstrated the

possible involvement of GSK-3 in schizophrenia. Although GSK-3β knockout mice die
in utero, GSK-3β heterozygous knockout mice are viable and display decreases in
exploratory activity and reduced locomotor activity to amphetamine148,

201, 202

. GSK-

3α knockout mice are viable and exhibited a decrease in locomotion to a novel
environment and impaired sensorimotor gating203.

1.7.2 Akt and Schizophrenia
An association between schizophrenia and Akt-1 genetic variants has been
reported in several independent cohorts of schizophrenic patients48-53. Reduced Akt-1
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protein levels have been reported in the frontal cortex of schizophrenic patients but no
difference in Akt-2 or Akt-3 protein levels were observed49. Furthermore, an Akt-1 gene
variant found in some schizophrenic patients has been linked to cognitive functioning
including IQ, processing speed and executive cognitive control processes204.

These

cognitive measures have been associated with dopaminergic functioning and impairments
in these cognitive measures are observed in patients with schizophrenia. This same
genotype predicted reduced gray matter volume in the right PFC and bilateral caudate
and was correlated to dopaminergic functioning204. Reduction in gray matter volume is a
common feature in schizophrenia143.
In animal studies, Akt-1 knockout mice do not display abnormalities in PPI,
spatial working memory or locomotor activity compared with wild-type littermates49, 205.
However, Akt-1 knockout mice exhibit disruptions in these behavioural tests when
challenged with dopamine receptor agonists, suggesting that Akt-1 modulation of these
behaviours is influenced by the dopaminergic environment49, 205. It is known that stress
influences dopamine levels and is often a trigger for psychosis or a relapse206. Thus, an
Akt-1-environment interaction may affect the expression and severity of functioning in
patients with schizophrenia. Furthermore, Akt-1 knockout mice show changes in the
dendritic architecture of pyramidal neuron in the PFC (layer V neurons), the output
neurons of the cortex205. Abnormalities in the cytoarchitecture of the pyramidal neurons
is a common feature in schizophrenia143. Taken together, the human and animal studies
implicate Akt-1 in modulating prefrontal-striatal structures and function and thus may be
relevant in certain symptoms of schizophrenia.
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1.7.3 Wnt and Schizophrenia
The Wnt pathway is essential for proper development of the central nervous
system in general and dopaminergic neuron development in particular. Wnt-3a promotes
the proliferation of ventral midbrain DA neurons, whereas Wnt-1 and Wnt-5a are
involved in the differentiation of DA neurons207-209. Other studies have demonstrated that
GSK-3-β-catenin signalling is involved in proliferation and differentiation of ventral
midbrain DA neurons210,

211

. These results suggest that the canonical Wnt pathway

regulates DA neuron development. Thus, dysregulation of the canonical Wnt pathway
may lead to improper DA neuron development, a neurotransmitter system strongly
implicated in schizophrenia.
Abnormalities in Wnt signalling have also been demonstrated in schizophrenia.
Genetic studies have shown an association between the Frizzled-3 receptor gene and
schizophrenia212-214. Two members of the dickkopf (DKK) family, negative regulators of
the Wnt pathway, have been implicated in schizophrenia. DKK4 has been identified as a
possible schizophrenia susceptibility gene215 and reductions in DKK3 mRNA levels have
been observed in the temporal cortex of schizophrenics216. Alterations in Wnt-1 and βcatenin staining have also been found in the hippocampus217,

218

. In addition, animal

studies have shown that disruptions in Wnt signalling leads to abnormalities in social
interaction and hyperlocomotion, common behavioural measures used in schizophrenia
research. Dvl-1 deficient mice exhibited abnormal social interactions219. Transgenic
mice overexpressing β-catenin inhibited amphetamine-induced hyperlocomotion220.
Taken together the data suggests a potential role for the Wnt pathway in schizophrenia.
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1.8 mGLUR2/3 AGONISTS
Several attempts have been made to find alternative drug treatments for
schizophrenia that do not target the D2DR in the hopes of obtaining pharmaceuticals with
improved clinical efficacy and fewer side-effects. For example, drugs that specifically
target serotonin (5-HT2) receptors, D4DR, D1DR and 5-HT2/D4DR have been developed
but have failed to show any clinical antipsychotic activity. However, there is recent
evidence to suggest that mGluR2/3 agonists may be effective for the treatment of
schizophrenia. Initial animal studies showed that mGluR2/3 agonists, LY379268 and
LY404039 attenuated hyperlocomotion in amphetamine-sensitized and PCP treated
rats221.

Studies in healthy human subjects reported that the mGluR2/3 agonist,

LY354740 improved working memory in ketamine treated subjects104. In addition, data
from an early clinical trial suggests that the group II metabotropic glutamate receptor
agonist LY2140023 may have antipsychotic properties105. Treatment with LY2140023
was reported to improve the positive symptoms of schizophrenia with comparable
efficacy to olanzapine, an atypical antipsychotic and also improved negative symptoms in
patients105. Thus, mGluR2/3 agonists may represent an alternative, non-dopaminergic
treatment for schizophrenia. However, the molecular mechanism responsible for the
ability of mGluR2/3 agonists to alleviate psychosis is unknown.

33
1.9 OVERVIEW
GSK-3 has been implicated in the manifestation of schizophrenia and the alleviation
of the positive symptoms of schizophrenia. Postmortem studies have reported reductions
in total194 and phosphorylated GSK-3 levels49, whereas increases in total and
phosphorylated GSK-3 levels in the PFC of rats have been observed following
antipsychotic treatment222. There is also evidence that Akt and the Wnt pathway, two
cascades that regulate GSK-3 are disrupted in schizophrenia and targeted by
antipsychotics.

Akt-1 and members of the Wnt pathway have been identified as

susceptibility genes for schizophrenia and/or altered protein, mRNA and/or
phosphorylation levels have been reported176. Repeated treatment with haloperidol or
clozapine increases Dvl-3 and β-catenin but has no effect on Dvl-1 or Dvl-2 protein
levels in the PFC of rats222. In addition, haloperidol treatment has been shown to increase
pAkt at Thr308 and Ser473 in the frontal cortex of rats49. However, it is unknown if
there is a convergence of Akt and Wnt and how the coordinated action of Akt and Wnt
may affect GSK-3. Thus, in chapter two, the role of Akt and Dvl-3 in regulating GSK-3
and the transcription factor β-catenin in the PFC was investigated. One of the major
concerns with linking GSK-3 signalling to the ability of antipsychotics to alleviate
psychosis is specificity. Several other neuropsychiatric drugs that are unable to alleviate
psychosis, such as mood stabilizers and antidepressants, also regulate GSK-3. In the
third chapter, the study compared the effects of antipsychotic, mood stabilizers and
antidepressants on Akt and Wnt pathway proteins to determine if antipsychotics have a
specific effect(s) on these pathways. Finally, the fourth chapter addressed whether Akt
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and/or the Wnt pathway are affected by mGluR2/3 signalling, given the recent promise of
mGluR2/3 in the treatment of schizophrenia.

1.10 OBJECTIVES AND RATIONALE
1.10.1 Alterations in GSK-3 and Akt signalling induced by the D2DR are mediated
by Dvl-3
Rationale:
Previous studies have shown that antipsychotic treatments induce a common and specific
pattern of change on Akt and the Wnt pathway, two signalling cascades that regulate
GSK-3. Antipsychotics, such as haloperidol, clozapine and/or risperidone increase pAkt,
Dvl-3, GSK-3, pGSK-3 and β-catenin in the PFC150, 222. All antipsychotics are D2DR
antagonists and it is thought that blockade of the D2DR is involved in the ability of
antipsychotics to alleviate psychosis162.

Subsequently, it has been suggested that

antipsychotics mediate their effects on Akt and the Wnt through the blockade of the
D2DR. Although it is known that the D2DR can regulate Akt167, it is unclear if changes in
the Wnt pathway are mediated by the D2DR or by other dopamine receptors.
Furthermore, given that antipsychotics induce changes in Akt and Dvl-3, suggest a
possible convergence of these cascades on GSK-3 and consequently β-catenin.

Hypothesis:
D2DR regulates GSK-3 by targeting Dvl-3 and Akt.
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Objectives:
-

To examine whether the Wnt pathway is regulated by the D1DR, D2DR and/or
D3DR.

-

To identify and then elucidate how the pattern of change in GSK-3, Akt and select
Wnt proteins were induced by the D2DR.

1.10.2 The effect of neuropsychiatric drugs and amphetamine on GSK-3 related
signalling
Rationale:
GSK-3 has been implicated in schizophrenia, mood disorders and depression and in their
treatment options, antipsychotic drugs, mood stabilizers and antidepressants, respectively.
Reduction in total and phosphorylated GSK-3 protein levels have been reported in the
frontal cortex of schizophrenic patients194,

223

. In contrast, several antipsychotics have

increased total and phosphorylated GSK-3 protein levels in the prefrontal cortex of
rats150,

224

.

Mood stabilizers and antidepressants have also been shown to increase

phosphorylated GSK-3 protein levels in vivo225-229. However, the clinical profile of
antipsychotics, mood stabilizers and antidepressants are different, and only antipsychotics
are able to alleviate psychosis. Thus, it has been suggested that if GSK-3 signalling is
important for the therapeutic effects of antipsychotics, then there may be differences in
the regulation of GSK-3 compared to other neuropsychiatric drugs. Antipsychotics have
been shown to activate Akt and the Wnt pathway in vivo, two cascades that inhibit GSK349,

222

. The effects of mood stabilizers and antidepressants on Akt and/or the Wnt

pathway

may

provide

key

differences in

neuropsychiatric drugs and antipsychotics.

GSK-3

signalling between these
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Hypothesis:
Haloperidol and clozapine treatments induce a specific response on Akt and the Wnt
pathway leading to the stabilization of β-catenin, which is not mimicked by lithium,
valproic acid, imipramine or fluoxetine.

Objectives:
-

To compare the effects of antipsychotics (haloperidol and clozapine), mood
stabilizers (lithium and valproic acid) and antidepressant (fluoxetine and
imipramine) on Akt, Dvl, GSK-3 and β-catenin in the PFC and STR of rats.

-

To investigate the association between GSK-3 and Akt and the D2DR complex
following haloperidol, clozapine, lithium and valproic acid.

-

To examine changes in Akt, Dvl-3, GSK-3 and β-catenin in the PFC and STR of
the amphetamine model.

1.10.3 Regulation of Akt and Wnt signalling by the group II metabotropic
glutamate receptor antagonist LY341495 and agonist LY379268
Rationale:
Metabotropic glutamate receptors 2/3 (mGluR2/3) have been implicated in schizophrenia
and as a potential treatment option for certain symptoms of schizophrenia. Genetic
studies have identified the mGluR3 as a possible susceptibility gene for schizophrenia94,
95

and have shown that these influence certain aspects of cognition (i.e. attention and

verbal learning)94. A preclinical trial has shown that treatment of the mGluR2/3 agonist,
LY2140023 (prodrug of LY404039) led to an improvement of positive and negative
symptoms, compared to placebo105.

Animal studies have reported treatment with
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mGluR2/3 agonists (LY379268, LY404039 or LY354740) attenuated amphetamine and
PCP induced hyperlocomotion221,

230-233

. Although there is strong evidence suggesting

mGluR2/3 agonists have antipsychotic-like properties, the molecular mechanism(s) that
explain how activation of mGluR2/3 alleviates psychosis is unknown. Given that Akt
and the Wnt pathway are implicated in traditional antipsychotic drug action, Akt and Wnt
may represent potential targets for mGluR2/3 agonists.

Hypothesis:
Metabotropic glutamate receptors 2/3 regulates Akt, GSK-3 and the Wnt pathway leading
to functional changes at the metabotropic glutamate receptor 2/3 complex.

Objectives:
-

To investigate the effects of the mGluR2/3 agonist LY379268 and the mGluR2/3
antagonist LY341495 on Akt, Dvl, GSK-3 and β-catenin in the PFC and STR.

-

To examine the association between the mGluR2/3 and Akt, Dvl and GSK-3 in
the PFC and/or STR.

-

To examine the effects of the mGluR2/3 antagonist, LY341495 on locomotion.
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CHAPTER TWO
Alterations in GSK-3 and Akt signalling induced by the D2DR are
mediated by Dvl-31

1

Sections 2.1-2.5 have been submitted to Biological Psychiatry.
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2.1 INTRODUCTION
Converging lines of research have implicated Akt and the Wnt pathway in
schizophrenia and antipsychotic drug action. Reductions in Akt-1 protein levels in the
frontal cortex of some schizophrenic patients has been reported and Akt-1 has been
identified as a potential schizophrenia susceptibility gene in several independent studies16

. Postmortem studies have shown a decrease in GSK-3β protein and mRNA levels in the

frontal cortex of schizophrenic patients7,

8

and GSK-3β has been linked genetically to

schizophrenia9, 10. Proteins involved in Wnt signalling such as the Frizzled-3 receptor,
Wnt-1, Dickkopf 3 and Dickkopf 4 have been linked to schizophrenia or were shown to
have altered protein levels in postmortem studies11-15. In contrast, antipsychotics have
been shown to increase phosphorylated Akt, Dvl-3 and GSK-3 protein levels in the PFC
of mice or rats2, 16, 17.
The Wnt pathway and Akt both negatively regulate GSK-3 (GSK-3α and GSK3β), although the mechanisms by which these pathways inhibit GSK-3 differs.
Traditional models of Wnt signalling suggest that GSK-3 forms a complex with other
proteins allowing for the phosphorylation of the transcription factor β-catenin, thereby
targeting it for degradation18, 19. Stimulation of the Wnt pathway activates the signal
transducer protein Dvl. Dvl interferes with the GSK-3 protein complex responsible for
phosphorylating β-catenin20,

21

.

Unphosphorylated β-catenin accumulates in the

cytoplasm and translocates to the nucleus where it regulates TCF/LEF gene
transcription22, 23 . Activation of Akt results in the subsequent phosphorylation of GSK-3
(ser21/9, GSK-3α/GSK-3β) and a reduction in GSK-3 kinase activity24, 25. Since both
Dvl and Akt can regulate GSK-3, there may be a convergence of these two signalling
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cascades at GSK-3 leading to the regulation of β-catenin. Similar to Akt and GSK-3, βcatenin is of interest since it has also been implicated in schizophrenia26 and
antipsychotic drug action16.
Antipsychotics have been shown to target Akt, GSK-3 and β-catenin, presumably
through the D2DR, since all antipsychotics are D2DR antagonists. This is of particular
interest given that D2DR antagonism is thought to be essential for alleviating psychosis27,
. Recent studies have shown that the D2DR can regulate Akt signalling in the brain29, 30

28

but it is unclear if the D2DR can also control the Wnt pathway. The current study
investigated whether D2DR antagonism can regulate the Wnt pathway leading to
increased levels of β-catenin and compared these results with D1DR and D3DR
antagonism. Furthermore, the role of Akt and Dvl-3 in the regulation of GSK-3 and βcatenin was investigated using both in vivo and in vitro approaches.

2.2 MATERIAL AND METHODS
2.2.1 Animal treatment
Adult male Sprague-Dawley rats 14+ weeks of age were housed in pairs with free access
to food and water on a 12 hr light/dark cycle. Rats were injected with SCH23390 (D1DR
antagonist, 0.5mg/kg, s.c., Sigma-Aldrich), raclopride (D2DR antagonist, 3mg/kg,
intramuscular, Sigma-Aldrich), nafadotride (D3DR antagonist, 0.5mg.kg, s.c., SigmaAldrich), quinpirole (D2DR agonist, 3mg/kg, intramuscular, Tocris) or appropriate
vehicles for 7 days (n=8/treatment).

The doses selected are routinely used in the

literature and/or based on behavioural studies involving prepulse inhibition31 and in vivo
dopamine receptor occupancy studies32-34. Rats were sacrificed 2 hours following the
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final injection of SCH23390, raclopride or nafadotride and 4 hours following the final
treatment with quinpirole. Post-injection times were selected based on empirical data
from the laboratory showing robust and consistent changes in Wnt/Akt proteins at these
time points.

Brains from Akt-1 knockout, heterozygous and wild type mice were

generously provided by Dr. F. Beier (University of Western Ontario, Canada) although
originally obtained from Jackson Laboratories.

All experiments were conducted in

accordance with the Canadian Council on Animal Care (CCAC) in a CCAC approved
facility at the University of Western Ontario. Every effort was made to reduce the
number of animals used in the study and to minimize suffering.

2.2.2 Cell culture
SH-SY5Y (neuroblastoma) cells were grown in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS) and penicillin (100U/ml)/streptomycin (100μg/ml) and were
maintained in a humidified 37ºC incubator with 5% CO2.

2.2.3 Retroviral infections and transfections
For Dvl-3 overexpression, SH-SY5Y cells were infected with Dvl-3 or control (nAP2)
retrovirus as previously described17. Overexpression of Dvl-3 alone was shown to be
sufficient to initiate Wnt signalling and mimic the affects of antipsychotics on the Wnt
pathway in vivo17. To increase Akt activity, SH-SY5Y cells were transfected with a
constitutively active Akt (myrAkt Δ4-129) or control construct (A2myrAkt Δ4-129) that
does not alter Akt activity35 using Lipofectamine 2000 (Invitogen) according to the
manufacturer’s instructions. The Akt vectors were generously provided by Dr. R. Roth
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(Stanford University School of Medicine, California). To knockdown Akt-1 and Dvl-3
protein levels, SH-SY5Y cells were transfected with siRNA specific for Akt-1 or Dvl-3.
Briefly, cells were plated in a 6-well plate (50,000cells/well) and allowed to adhere
overnight. The cells were transfected with siRNA for Akt-1 (Ambion, s659), Dvl-3
(Ambion, s674) or a negative control siRNA (Ambion) at a concentration of 30pmol
using Lipofectamine RNAiMAX (Invitrogen) and Optimem I media according to the
manufacturer’s instructions.

2.2.4 PI3-K inhibitor treatments of cell cultures
SH-SY5Y cells were treated with varying concentrations of the PI3-K inhibitors
wortmannin (Calbiochem), LY294002 (Calbiochem) or vehicle (control) in serum
reduced (1% FBS in DMEM) media. The PI3-K inhibitors wortmannin and LY294002
were selected since they are routinely used in the literature to inhibit PI3-K-Akt
phosphorylation. Briefly, cells were plated on 60mm plates (300,000 cells) and allowed
to adhere overnight. The next day media was replaced with fresh serum reduced media
and treated with wortmannin (0.1μM, 1μM or 10μM), LY294002 (2μM, 20μM or 40μM)
or vehicle (controls) for 1 hour (n = 6/treatment). In a separate series of experiments,
SH-SY5Y were infected with Dvl-3 or nAP2 and treated with wortmannin (10μM),
LY294002 (40μM) or vehicle alone (n = 6/treatment).

2.2.5 Protein isolation and western blotting
Protein isolation, quantification and western blotting were conducted as previously
outlined for the PFC tissue16 or for cells17. Densitometry values were obtained from X-
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ray film using a grey scale calibrated scanner (Epson) and Kodak Molecular Imaging
software. Densitometry values were corrected for α-tubulin and expressed as a
percentage of control. The data was analyzed using an ANOVA followed by Tukey’s
multiple comparison test or Student’s t-test as appropriate. The source and dilution of the
antibodies used in the study were as follows: Akt (Cell Signalling Technology, 1:1250),
Akt-1 (Cell Signalling Technology, 1:1000), Akt-2 (Cell Signalling Technology, 1:1000),
Akt-3 (Cell Signalling Technology, 1:1000), phospho-Akt Ser473 (Cell Signalling
Technology, 1:1000), phospho-Akt Thr308 (Upstate, 1:1000), Dvl-1 (Santa Cruz
Biotechnology, 1:100), Dvl-2 (Chemicon, 1:1000), Dvl-3 (Santa Cruz Biotechnology,
1:100), GSK-3 (Santa Cruz Biotechnology, 1:300), phospho-GSK-3 (Ser21/9, Cell
Signalling Technology, 1:1000), β-catenin (Sigma-Aldrich, 1:20000), D2DR (Santa Cruz
Biotechnology, 1:100 rabbit and goat polyclonal) and α-tubulin (Sigma-Aldrich,
1:120000).

2.2.6 Co-Immunoprecipitations
Protein was isolated from the PFC of drug naïve rats or untreated SH-SY5Y cells using a
non-denaturing lysis buffer with the addition of protease (Complete Mini, Roche
Diagnostic) and phosphatase inhibitors (Cocktail Set 2, Sigma-Aldrich; Cocktail Set IV,
Calbiochem) as outlined previously17. Immunoprecipitations (IPs) were conducted using
the ExtraCruz IP system (Santa Cruz Biotechnology) with antibodies for D2DR (2μg/IP,
Santa Cruz Biotechnology, goat and rabbit polyclonal) or GSK-3α/β (3μg/IP, Santa Cruz
Biotechnology) and 500μg of protein. As a control, protein samples (500μg) were
immunoprecipitated with IgG (Santa Cruz Biotechnology) from the same species as the
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IP antibody. IPs were also conducted with protein (500μg) isolated from the PFC of
raclopride, quinpirole or vehicle treated rats or SH-SY5Y cells infected with Dvl-3 or
transfected with a constitutively active Akt construct using the ExtraCruz system and
antibodies specific for D2DR (2μg/IP, Santa Cruz Biotechnology, goat and rabbit
polyclonal). The IP samples were subjected to western blotting (WB) and probed for the
proteins of interest; D2DR (Santa Cruz Biotechnology, 1:100), GSK-3 (Santa Cruz
Biotechnology, 1:300) or Akt (Cell Signalling Technology, 1:1250).

2.3 RESULTS
2.3.1 Regulation of Akt and Wnt pathway proteins by D1DR, D2DR and D3DR
Raclopride was used to determine whether D2DR antagonism is able to mediate
changes in Akt and the Wnt pathway in the PFC. The results showed that raclopride
increased Dvl-3, GSK-3α/β, pGSK-3α/β and β-catenin protein levels but had no effect
on Dvl-1 or Dvl-2 (Figure 2.1a and b). Raclopride also increased the phosphorylation
state of Akt Thr308 and Ser473 but did not affect total Akt levels (Figure 2.1c and d). To
determine if Akt and/or Wnt pathway proteins are regulated by other dopamine receptors,
D1DR and D3DR antagonists were also used. SCH23390 (D1DR antagonist) had no
effect on any of the Wnt pathway proteins tested (Figure 2.1a and b) or on the total and
phosphorylated levels of Akt (Figure 2.1c and d).

Nafadotride (D3DR antagonist)

increased pGSK-3α/β but had no effect on Dvl-1, Dvl-2, Dvl-3, GSK-3α/β or β-catenin
(Figure 2.1a and b). Nafadotride also increased pAkt Ser473 but did not alter total Akt or
pAkt Thr308 levels (Figure 2.1 c and d).
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Figure 2.1: The effects of D1DR, D2DR and D3DR antagonism on total protein levels
and/or phosphorylation state of Akt and Wnt pathway proteins.
(a) Representative blots and (b) graph of densitometry values for Dvl, GSK-3α/β and βcatenin in the PFC of rats treated with SCH23390 (D1DR antagonist), raclopride (D2DR
antagonist) or nafadotride (D3DR antagonist). (c) Representative blots and (d) graph of
densitometry values for total and phosphorylated Akt in the PFC of rats treated with
SCH23390, raclopride or nafadotride. For each representative western blot, the left band
represents the vehicle (V) while the right band shows the drug treatment (D). The graphs
compare densitometry values obtained from the western blots, with control values set at
100%. For simplicity, the graphs are shown using a single control. Statically significant
changes are denoted by the asterisk (p < 0.05, n=8). Error bars represent the standard
error of the mean.
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Hyperdopaminergic animal models, such as the DAT-KO mice and amphetaminesensitization have been shown to inhibit Akt and/or Wnt signalling29, 36. To determine if
the D2DR may be responsible for these changes, the D2DR agonist quinpirole was used.
Quinpirole caused decreases in Dvl-3, GSK-3α/β, pGSK-3α/β and β-catenin but had no
effect on Dvl-1 or Dvl-2 in the PFC (Figure 2.2a and b). Decreases in pAkt Ser473 were
also found but no changes in total Akt or pAkt Thr308 were detected (Figure 2.2c and d).
Previous studies showed an association between the D2DR complex and Akt and
Dvl-317 and an association between Akt and GSK-337.

Consequently, co-IP’s were

conducted to determine if there is an association between D2DR and GSK-3.

IPs

conducted using an antibody for D2DR followed by a WB for GSK-3α/β showed an
association between the D2DR complex and GSK-3α/β (Figure 2.3a). A similar result
was observed when IPs were conducted using a GSK-3α/β specific antibody followed by
a WB for D2DR (Figure 2.3b). The results indicate that GSK-3α/β is associated with the
D2DR complex in naive PFC tissue. In addition, since D2DR antagonists (raclopride and
antipsychotics) activate the Wnt pathway and a previous study showed that activation of
the Wnt pathway causes translocation of GSK-3 to the membrane38, co-IPs were
performed using protein isolated from the PFC of raclopride treated rats to determine if
the association between the D2DR complex and Akt and/or GSK-3 is altered. The results
showed that the association between D2DR and Akt is unaltered (102.1% ± 7.9, n=4) and
as expected the total Akt levels in the lysate samples were unaffected (90.5% ± 6.7, n=4)
(Figure 2.3c). D2DR levels were also not significantly altered following the raclopride
treatment (98.9 ± 3.0, n=4) (Figure 2.3c). However, there is an increased association
between D2DR and GSK-3α/β following raclopride treatment (Figure 2.3c and d). There
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Figure 2.2:

The effects of D2DR agonism on total protein levels and/or
phosphorylation state of Akt and Wnt pathway proteins.

(a) Representative blots and (b) graph of densitometry values for Dvl, GSK-3α/β and βcatenin in the PFC of rats treated with quinpirole. (c) Representative blots and (d) graph
of densitometry values for total and phosphorylated Akt in the PFC of rats treated with
quinpirole. For each representative western blot, the left band represents the vehicle (V)
while the right band shows the drug treatment (D). The graphs compared the
densitometry values obtained from the western blot. Densitometry values are expressed
as a percentage of control ± SEM and statistically significant differences are indicated by
the asterisks (p < 0.05, n=8).
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Figure 2.3: Co-IP experiments showing the association between D2DR and Akt or
GSK-3α/β in drug naïve rats, raclopride or quinpirole treated rats.
(a) Protein samples were obtained from the PFC of drug naïve rats and
immunoprecipitated (IP) with a D2DR antibody. IP samples were subjected to western
blotting (WB) and probed GSK-3α/β (+ lanes). (b) Protein samples from the PFC of
drug naïve rats were IP with a GSK-3α/β antibody and IP samples were then subjected to
WB and probed for D2DR (+ lanes). For the negative control lanes, co-IPs were
conducted using a non-specific IgG in place of the IP antibody (- lanes). Protein samples
obtained from the PFC of (c) raclopride or (e) quinpirole treated rats were IP with a
D2DR antibody. IP samples were subjected to WB and probed for D2DR, Akt and GSK3α/β (upper panels). WB were also conducted using the same lysate as the IPs to
compare changes in total protein levels in the samples (lower panel). Table of
densitometry values obtained from the (d) raclopride or (f) quinpirole co-IPs for
D2DR/GSK-3α/β and total GSK-3α/β protein levels. Statistically significant changes are
represented by an asterisk (p < 0.05, mean ± SEM, n=6).
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was also an increase in total GSK-3α/β protein levels (Figure 2.3c and d) consistent with
the previous findings. The results show that the increase in the association between
D2DR and GSK-3α/β is greater than the increase in total GSK-3α/β protein levels
(Figure 2.3d). Co-IP’s were also conducted using protein isolated from quinpirole treated
rats. Similar to raclopride, quinpirole had no affect on the association between D2DR and
Akt (97.3 ± 5.5, n=4) and no change in total Akt levels in the lysate samples (97.7 ± 5.3,
n=4) (Figure 2.3e). No change in the D2DR protein levels were detected in the lysate
samples (93.0 ± 7.1, n=4) (Figure 2.3e). A decrease in the association between D2DR
and GSK-3α/β and a reduction in total GSK-3α/β protein levels in the lysate samples
were observed following quinpirole treatment (Figure 2.3e and f).

The change in

association of GSK-3α/β with the D2DR complex, however, paralleled reductions in total
GSK-3α/β protein levels in the lysate (Figure 2.3f).

2.3.2 The effects of Akt on GSK-3 and β-catenin
To understand the role Akt may play in the pattern of change observed in vivo, Akt
activity was either increased or inhibited in SH-SY5Y cells to parallel the changes
observed following raclopride or quinpirole treatment, respectively. To increase Akt
activity, SH-SY5Y cells were transfected with a constitutively activate Akt construct.
Overexpression of constitutively active Akt resulted in increased pGSK-3α/β but had no
effect on total GSK-3α/β or β-catenin protein levels compared to control (Figure 2.4a and
b). To inhibit Akt activity, the PI3-K inhibitors wortmannin or LY294002 were used.
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Figure 2.4: The effect of a constitutively active Akt construct or Akt inhibitors,
wortmannin and LY294002 on GSK-3 and β-catenin in SH-SY5Y
cells.
(a) Representative western blots and (b) graph comparing densitometry values showing
the effects of constitutively active Akt (myrAkt) or control vector (vector) for GSK-3α/β,
pGSK-3α/β and β-catenin. For each western blot the left band represents the control
vector and the right band represents the constitutively active Akt. (c) Representative
western blots and (d) graph showing the densitometry values obtained from western blots
following wortmannin treatment (0.1μΜ, 1μM and 10μΜ) for Akt, pAkt Thr308, pAkt
Ser473, Dvl-3, GSK-3α/β, pGSK-3α/β and β-catenin.
(e) Graph showing the
densitometry values obtained from western blots following LY294002 treatment
(2μΜ, 20μM and 40μΜ). Densitometry values are expressed as a percentage of control ±
SEM and statistically significant differences are indicated by the asterisks (p < 0.05,
n=8).
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Wortmannin (Figure 2.4c and d) and LY294002 (Figure 2.4e) treatments caused
significant reductions in pAkt Thr308, pAkt Ser473 and pGSK-3α/β at 10μM and 40μM
respectively but did not affect Dvl-3, GSK-3α/β or β-catenin at any dose tested.
The initial overexpression and pharmacological experiments targeted total Akt
activity and suggested that Akt regulates the phosphorylation of GSK-3 alone. Further
analysis was conducted using Akt-1 siRNA and an Akt-1 deficient mice since Akt-1
protein levels were found to be altered in schizophrenia post-mortem samples2.
Knockdown of Akt-1 by siRNA nearly abolished Akt-1 protein expression but also
caused a compensatory increase in Akt-3 protein levels (174.2% ± 5.9, n=6) (Figure
2.5a). Akt-2 was not readily detectable in SH-SY5Y cells and was not examined further
in this cell line. Despite the increase in Akt-3, knockdown of Akt-1 resulted in decreased
pGSK-3α/β but had no effect on Dvl-3, GSK-3α/β or β-catenin protein levels (Figure
2.5a and b). To determine if similar results are obtained in vivo, Akt-1 transgenic mice
were used. Compared to wild-type littermates, a decrease in pGSK-3α/β was observed in
the PFC of Akt-1 heterozygous (+/-) and Akt-1 knockout (-/-) mice (Figure 2.5c and d).
However, no significant change in Akt-2, Akt-3, Dvl-3, GSK-3α/β or β-catenin proteins
levels were detected in either Akt-1 heterozygous or Akt-1 knockout mice (Figure 2.5c
and d).

2.3.3 The effects of Dvl-3 on Akt, GSK-3 and β-catenin levels
Dvl-3 protein levels were increased following raclopride treatment and increased
levels of Dvl/Dvl-3 have been shown to be sufficient to activate the Wnt pathway17.
Consequently, Dvl-3 was overexpressed in SH-SY5Y cells to examine the effects of
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Figure 2.5: The effects of reducing Akt-1 protein levels in vitro and in vivo on Akt,
Dvl-3, GSK-3 and β-catenin using siRNA or transgenic mice,
respectively.
(a) Representative western blots and (b) graph showing the densitometry values obtained
from western blots of protein isolated from SH-SY5Y cells transfected with Akt-1 siRNA
or control siRNA. The band on the left represents the control siRNA and the band on the
right represents the Akt-1 siRNA. (c) Representative western blots and (d) graph showing
the densitometry values from western blots of protein isolated from the PFC of Akt-1
knockout (KO, n = 5), Akt-1 heterozygous (HZ, n = 4) or wild type (WT, n = 5) mice.
The densitometry values are expressed as a percentage of control with a statistically
significance difference denoted by an asterisk (p < 0.05, mean ± SEM).
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Dvl-3 on Akt, GSK-3 and β-catenin. Overexpression of Dvl-3, resulted in increased total
GSK-3, pGSK-3α/β and β-catenin protein levels but did not effect Dvl-1 or Dvl-2 levels
as previously reported (Figure 2.6a-c)17. In addition, Dvl-3 overexpression also increased
pAkt Thr308 and Ser473 without affecting total Akt protein levels (Figure 2.6a-c).
Although manipulations of Akt/Akt-1 activity/protein levels in vitro and in vivo
did not affect β-catenin levels, recent reports have suggested that Wnt activation of Akt
enhances the inhibition of GSK-339, 40. Therefore, it is possible that activation of Akt
may contribute to increased β-catenin levels in Dvl-3 overexpressing cells. To test this
possibility, SH-SY5Y cells infected with Dvl-3 were treated with either wortmannin or
LY294002 to determine if the inhibition of PI3-K-Akt can block the increase in β-catenin
and/or GSK-3 following Dvl-3 overexpression alone.

Results indicate that the

wortmannin (Figure 2.6a and b) and LY294002 (Figure 2.6c) treatments caused
significant reductions in pAkt Thr308, pAkt Ser473 and pGSK-3α/β levels. However,
the PI3-K inhibitors had no effect on β-catenin or GSK-3α/β in cells overexpressing Dvl3 (Figure 2.6a-c). Collectively, the results suggest that Akt regulates the phosphorylation
of GSK-3 whereas Dvl-3 regulates β-catenin and GSK-3 protein levels and is involved in
Akt activation.
To further examine the role of Dvl-3 in Akt, GSK-3 and β-catenin regulation, SHSY5Y cells were transfected with Dvl-3 siRNA.

The knockdown of Dvl-3 nearly

eliminated Dvl-3 protein expression but had no effect on either Dvl-1 or Dvl-2 (Figure
2.6d and e). Both GSK-3α/β and β-catenin protein levels were also reduced consistent
with the changes observed in quinpirole treated rats (Figure 2.6d and e). Interestingly,
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Figure 2.6: Changes in Akt, Dvl, GSK-3 and β-catenin following the overexpression
or knockdown of Dvl-3 in SH-SY5Y cells.

(a) Representative western blots and (b) graph showing the densitometry values obtained
from western blots following the overexpression of Dvl-3 or nAP2 treated with
wortmannin (10μM). (c) Graph showing the densitometry values obtained from western
blots following the overexpression of Dvl-3 or nAP2 treated with LY294002 (40μM).
(d) Representative western blots and (e) graph of densitometry values obtained from
western blots following the transfection of Dvl-3 or control siRNA. The left lane shows
the protein levels obtained from control siRNA while right lane shows the protein levels
from Dvl-3 siRNA transfected cells. The values are shown as a percentage of control ±
SEM and a statistical significance is denoted by (b, c) a difference in lettering or e) by an
asterisk (n=8, p<0.05).
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knockdown of Dvl-3 also caused a significant down regulation in Akt-1 but not Akt-3
(Figure 2.6d and e), similar to what was reported in postmortem tissue of schizophrenic
patients2. However, knockdown of Dvl-3 with siRNA did not significantly decrease pAkt
levels as anticipated (Thr308 98.28% ± 6.04; Ser473 84.27% ± 8.12, n=6).

2.3.4 D2DR association with GSK-3
The in vitro results suggest that Dvl-3 may be responsible for activation of Akt
and the Wnt pathway following raclopride treatment. Therefore, it is plausible that
upregulation of Dvl-3 may also be responsible for the translocation of GSK-3 to the
D2DR complex observed following raclopride treatment. To test this hypothesis, co-IPs
were performed using protein isolated from Dvl-3 overexpressing SH-SY5Y cells. The
D2DR is endogenously expressed in SH-SY5Y cells and initial experiments indicated that
Akt and Dvl-3 are associated with the D2DR complex in untreated cells (Figure 2.7a)
similar to what was seen in the PFC of drug naïve rats41. Overexpression of Dvl-3 led to
an increased association between the D2DR complex and GSK-3β (Figure 2.7b and
c). Αn increase in total GSK-3β protein levels were also observed in the lysate samples
(Figure 2.7b and c). The results show that the increase in GSK-3β associated with the
D2DR complex was greater than the increase in total GSK-3β protein levels induced by
Dvl-3 overexpression (Figure 2.7c) consistent with raclopride treatment in vivo. Cells
transfected with constitutively active Akt did not alter the relationship between the D2DR
complex and GSK-3α/β nor was there a change in GSK-3α/β protein levels in the lysate
samples (Figure 2.7d and e).
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Figure 2.7: Co-IP experiments examining the association between D2DR and GSK3α/β in native SH-SY5Y cells or following viral overexpression of Dvl-3
or transfection with a constitutively active Akt construct.
(a) Protein from treatment naïve SH-SY5Y cells were IP with a D2DR antibody. IP
sample were subjected to WB and probed using D2DR, Akt or Dvl-3 antibodies (+ lane).
For the negative control, co-IP’s were conducted using a non-specific IgG in place of the
IP antibody (- lane). (b) Protein samples obtained from SH-SY5Y cells infected with
Dvl-3 or nAP2 (Cont) or (d) transfected with Akt construct (myrAkt) or empty vector
(Cont) were IP with D2DR antibody. IP samples were subjected to WB and probed using
GSK-3α/β antibody (upper panel). WB were also conducted using the same lysate as the
IPs and probed using GSK-3α/β antibody to demonstrate changes in total protein levels
in the lysate sample (lower panel). Table of the densitometry values for co-IPs and total
GSK-3β protein levels for (c) the overexpression of Dvl-3 or (e) constitutively active
Akt. Statistically significant changes are represented by an asterisk (p < 0.05, mean ±
SEM, n=6).
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2.4 DISCUSSION
The in vivo results of the current study show that D1DR and D3DR do not affect
the Wnt pathway, although D3DR can regulate pAkt. D2DR, in contrast, can regulate
both the Akt and Wnt pathways. These results are consistent with a previous study
showing altered Akt signalling in D2DR and D3DR but not D1DR knockout mice30.
Antagonism of the D2DR by raclopride results in reduced levels of Dvl-3, GSK-3α/β, βcatenin and pAkt.

The findings are consistent with previous studies showing that

antipsychotics, haloperidol and/or clozapine increase Dvl-3, GSK-3α/β and β-catenin and
pAkt levels and that the D2DR is associated with Akt2, 16, 17. The results also suggest that
the increases in the phosphorylation state of Akt and in levels of Wnt pathway proteins
observed following antipsychotic treatment are mediated by the D2DR, an important
finding given that the D2DR is thought to be essential for the therapeutic effects of
antipsychotics27, 28. In contrast, agonism of the D2DR by quinpirole resulted in decreased
levels of pAkt, Dvl-3, β-catenin and GSK-3α/β. These findings compliment previous
studies showing decreased pAkt levels in the STR of dopamine transporter knockout
mice and following amphetamine treatment29.
Raclopride and quinpirole led to increased or decreased pGSK-3α/β levels,
respectively. However, total GSK-3α/β levels were also altered. These findings are
consistent with previous results with antipsychotics and raclopride but complicate
interpretation of the data16. At this time it is not clear why total GSK-3α/β levels are
altered, although the in vitro results indicate it may be a consequence of Dvl-317.
The in vitro and Akt-1 knockout results suggest that Akt does not directly affect
Wnt signalling and parallels previous in vitro findings39, 40. Overexpression of activated
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Akt, pharmacological inhibition of PI3-K/Akt, knockdown of Akt-1 by siRNA and Akt-1
knockout mice all had no effect on β-catenin although changes in pGSK-3 were
consistently observed. However, recent studies have suggested that Akt may contribute
to TCF/LEF activation in Dvl-1 or Wnt-1 stimulated cells40, 42. Although the current
study found no synergistic effect of PI3-K/Akt and Dvl-3 on overall β-catenin levels,
differences in TCF/LEF activation cannot be excluded. Collectively, the data suggests
that changes in pAkt are responsible for the alterations in pGSK-3 but Akt does not
regulate β-catenin.
Traditionally, activation of the Wnt pathway has been described as binding of a
Wnt ligand to an appropriate Frizzled receptor leading to the phosphorylation and thus
activation of Dvl22, 43. However, it has also been shown that increased levels of Dvl are
sufficient to induce the formation of Dvl polymers and initiate the recruitment of Dvl to
the plasma membrane leading to activation of the Wnt pathway44,

45

. Therefore, an

increase or decrease in Dvl-3 protein levels may be sufficient for regulating the activity
of the Wnt pathway consistent with the observations that Dvl-3 overexpression and
knockdown of Dvl-3 with siRNA causes increases and decreases in β-catenin levels
respectively. In addition to β-catenin, Dvl-3 overexpression led to elevated levels of
GSK-3α/β and pGSK-3α/β as well as increased pAkt levels consistent to what was
observed following raclopride treatment. It is unclear how increasing Dvl-3 protein
levels cause an increase in Akt phosphorylation. However, the results are consistent with
previous cell culture studies showing that activation of the Wnt pathway by Dvl-1
overexpression or the addition of Wnt-3a to the media can cause increased Akt activity in
NIH 3T3 cells40, 46. The knockdown of Dvl-3 in vitro resulted in a pattern of change that
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was partially consistent with quinpirole treatment, suggesting that Dvl-3 may be
responsible for changes in GSK-3α/β and β-catenin following activation of the D2DR.
Surprisingly however, knockdown of Dvl-3 did not decrease pAkt levels, although
increases were observed following overexpression of Dvl-3. The reason for this disparity
is not clear. Reduction in Akt-1 protein levels caused by Dvl-3 knockdown was also
surprising but intriguing. In non-neuronal cell lines it has been shown that Akt-1 mRNA
and protein levels are regulated by β-catenin signalling47,
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and Akt-1 levels may be

reduced in schizophrenia2. Collectively, the data suggests that the D2DR regulates Wnt
signalling via Dvl-3 and that Dvl-3 may also regulate Akt signalling.
Dvl has been shown to be responsible for the translocation of Wnt pathway
proteins to the Frizzled receptor44. The overexpression of Dvl-3 in SH-SY5Y cells
caused increased association between GSK-3β and the D2DR complex. These results
suggest that Dvl-3 may be involved in the increase or decrease association of GSK-3α/β
and the D2DR complex following raclopride and quinpirole treatment, respectively. The
consequences of the altered association between GSK-3α/β and the D2DR are not clear.
However, it has been shown that activation of the serotonin 1B (5-HT1B) receptor leads
to an increased association with GSK-3 and that GSK-3 mediated phosphorylation of the
5-HT1B receptor helped retain the receptor at the cell surface49.

Others have also

demonstrated that GSK-3 effects the activity of the LPR6, the co-receptor for the Wnt
pathway via phosphorylation50, 51. Therefore, it is possible that the translocation of GSK3 to the D2DR complex may be involved in regulating D2DR activity.
While there is an association between GSK-3α/β and the D2DR, it is unclear how
these two proteins interact. It is possible that Dvl-3 mediates the interaction since Dvl-3
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is bound to the D2DR complex17 and can act as a scaffold for other proteins. The D2DR is
a well known G-coupled receptor and Dvl has recently been shown to possess a G protein
binding domain52, 53. In addition, β-arrestins may play a role in coupling the D2DR to
Dvl-3 and GSK-3. β-arrestin 2 is involved in mediating the effects of D2DR activity37
and an interaction between β-arrestin and Dvl has been reported54, 55. Furthermore, βarrestin 2 has been shown to be important for the regulation of Akt by the D2DR in vivo37.
However, an in vitro study showed that antipsychotics block the translocation of βarrestin 2 to the D2DR56 and Wnt activation would be expected to cause translocation of
Dvl-3 and GSK-3 to the D2DR. Finally, DISC-1 was recently shown to directly interact
with GSK-3 and regulate β-catenin levels57. Reduced levels of DISC-1 were shown to
reduce β-catenin levels whereas increased levels of DISC-1 increased β-catenin levels.
Disruption of DISC-1 in mice was also shown to cause schizophrenia-like behavioural
deficits that could be corrected by inhibition of GSK-357. However, it is not clear if
DISC-1 interacts with the D2DR. Therefore, there are several potential mechanisms
through which GSK-3 could interact with the D2DR but additional studies will be needed
to understand the precise nature of the relationship between D2DR, Akt and Wnt proteins.
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CHAPTER THREE
The effect of neuropsychiatric drugs and amphetamine on GSK- 3 related
signalling1

1

Sections 3.1-3.5 has been submitted to Journal of Neurochemistry.
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3.1 INTRODUCTION
GSK-3 is a constitutively active protein kinase that has been implicated in
schizophrenia and antipsychotic drug action. Decreases in total and phosphorylated
GSK-3β protein levels and a reduction in GSK-3β mRNA levels have been reported in
the brain of schizophrenia patients1, 2. GSK-3 protein levels and/or phosphorylation state
were also found to be decreased in several animal models of schizophrenia including
amphetamine-sensitization, the ventral hippocampal lesion model and the DAT-KO
mice3, 4. Furthermore, hyperlocomotor activity in DAT-KO mice, is reduced to wild-type
levels following treatment with inhibitors of GSK-35.

Antipsychotics, such as

haloperidol, clozapine and risperidone, in contrast, have been shown to increase total and
phosphorylated GSK-3α/β (Ser21/9) protein levels in the PFC and/or STR of rats
following repeated administration6, 7. Consequently, it has been suggested GSK-3 may
play a role in the manifestation and amelioration of some of the symptoms of
schizophrenia. However, in addition to schizophrenia, GSK-3 has also been implicated
in mood disorders and depression and mood stabilizers and antidepressants have been
shown to regulate the phosphorylation state of GSK-3 in vivo8-11. Antipsychotics, mood
stabilizers and antidepressants all have different clinical profiles and only antipsychotics
alleviate the positive symptoms of schizophrenia. Consequently, it has been suggested
that there may be something unique in the way GSK-3 is affected by antipsychotics
compared to drugs used to treat other neuropsychiatric disorders12.
GSK-3 function is regulated by several mechanisms including, phosphorylation,
association of GSK-3 with specific protein complexes (i.e. β-catenin phosphorylation
complex) and subcellular localization13, 14. Several signalling cascades are responsible
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for controlling the characteristics of GSK-3 but the Akt and Wnt pathways are of
particular interest given that they have both been linked to schizophrenia and
antipsychotic drug action7,

15

. Akt and the Wnt pathway negatively regulate GSK-3,

although via different mechanisms.

Akt reduces GSK-3 kinase activity through

phosphorylation of both isoforms of GSK-3 (ser21/9, GSK-3α/GSK-3β)16. The Wnt
pathway regulates GSK-3 through its association with the β-catenin phosphorylation
complex. GSK-3 associates with several proteins, including Axin and APC, forming a βcatenin phosphorylation complex that facilitates the phosphorylation and eventual
degradation of the transcription factor, β-catenin. Activation of the Wnt pathway leads to
the phosphorylation and/or increase in protein levels of the signal transducer protein
Dishevelled (Dvl). Dvl negatively regulates GSK-3 by interfering with the β-catenin
phosphorylation complex preventing the phosphorylation of β-catenin. The resultant
accumulation of β-catenin in the cytoplasm followed by its translocation to the nucleus
leads to modifications in TCF/LEF mediated gene transcription17.
Previous studies have shown that repeated treatment with the antipsychotics
haloperidol and/or clozapine target Akt and Wnt proteins in the PFC/frontal cortex6, 7, 15.
However, given that other neuropsychiatric drugs may regulate GSK-3 signalling, the
current study investigated whether the mood stabilizers, lithium and valproic acid and/or
the antidepressants, fluoxetine and imipramine mimic the effects of antipsychotics on Akt
and Wnt signalling or if there are key differences in the response of these drugs. In
addition, Akt and Wnt pathway proteins were also examined following repeated
treatment with the psychomimetic amphetamine.
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3.2 MATERIAL AND METHODS
3.2.1 Drug Paradigm
Adult male Sprague Dawley rats 14+ weeks of age (Charles River) were housed in pairs
in a 12 hour light/dark cycle with free access to food and water. Rats were injected once
daily with haloperidol (0.5mg/kg, i.m.), clozapine (25mg/kg, s.c.) or appropriate vehicle
for 14 days (n=8 rats/treatment). The doses of haloperidol and clozapine were based on a
previous study showing changes in the proteins of interest in the PFC and/or STR6. To
examine drug specificity, rats were injected with fluoxetine (10mg/kg, s.c., SigmaAldrich), imipramine (10mg/kg, s.c., Sigma-Aldrich) or appropriate vehicle for 14 days
(n=8 rats/treatment). Fluoxetine and imipramine were chosen since they represent two
different classes of antidepressants, and because they were found to alter phosphorylated
GSK-3 levels following acute treatment10. In addition, rats were treated with the mood
stabilizers, lithium or valproic acid via their chow or drinking water (n=8 rats/treatment).
Rats were fed chow containing 2.0g/kg LiCl or chow lacking LiCl for 30 days ad libitum.
Valproic acid (12g/L, Sigma Aldrich) was mixed in the rats’ drinking water and
supplemented with saccharin (300mg/L, Sigma Aldrich) for palatability, while the control
rats received drinking water supplemented with saccharin alone for 30 days. The doses
and delivery method for lithium and valproic acid were selected based on previous
studies showing they achieve clinically relevant serum concentrations in Sprague-Daley
rats18, 19. Finally, rats were injected with amphetamine (5mg/kg, i.p.) or saline (vehicle)
once daily for 10 days (n=8 rats/treatment). The PFC and STR of rats were isolated 2
hours following final treatment of haloperidol, clozapine, fluoxetine and imipramine. The
post-injection times were chosen as they were experimentally found to be optimal for
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detecting changes in expression of Akt and Wnt pathway proteins following
antipsychotics7, 15 and similar to an acute study showing changes in phosphorylated GSK3 following antidepressant treatments10. For amphetamine, a 4-hour post-injection
interval was selected based on a previous study showing reductions in β-catenin and
GSK-3 in the ventral midbrain20. Every effort was made to reduce the number of rats
used in the experiments and to minimize pain and suffering. All experiments were
reviewed and approved by the University of Western Ontario Animal research ethics
committee in compliance with Canadian Council on Animal Care.

3.2.2 Western blotting
Isolation of total protein from the PFC and STR, protein quantification and western
blotting was performed as previously outlined7. The PFC and STR were selected since
both regions have been implicated in neuropsychiatric disorders and have been
investigated with neuropsychiatric drugs. Densitometry values were obtained from X-ray
film using a grey scale calibrated scanner (Epson) and Kodak 1-D Molecular Imaging
software. Densitometry values were corrected for α-tubulin and expressed as a
percentage of control. Data was analyzed using an ANOVA followed by Tukey’s
multiple comparison test or Student’s t-test as appropriate. The source and dilution of the
antibodies used in the study were as follows; Dvl-1 (Santa Cruz Biotechnology, 1:100),
Dvl-2 (Chemicon, 1:1000), Dvl-3 (Santa Cruz Biotechnology, 1:100), GSK-3 (Santa
Cruz Biotechnology, 1:300), phospho-GSK-3 (Cell Signalling Technology, 1:1000), βcatenin (Sigma-Aldrich, 1:20000), Akt (Cell Signalling Technology, 1:1250), phospho-
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Akt Ser473 (Cell Signalling Technology, 1:1000), phospho-Akt Thr308 (Upstate, 1:1000)
and α-tubulin (Sigma-Aldrich, 1:120000).

3.2.3 Co-Immunoprecipitations
Protein was isolated from the PFC of haloperidol, clozapine, lithium, valproic acid and
amphetamine treated rats along with their appropriate vehicle controls using a nondenaturing lysis buffer containing protease (Complete Mini, Roche Diagnostic) and
phosphatase inhibitors (cocktail Set 2, Sigma-Adrich; cocktail Set IV, Calbiochem). Coimmunoprecipitations (co-IPs) were performed with the ExactaCruz system (SantaCruz
Biotechnology) according the manufacturers instructions using 500μg of protein and
antibodies specific for the D2DR (3μg/IP, Santa Cruz Biotechnology, rabbit and goat
polyclonal) as outlined previously6. Co-IP samples and lysate used in the co-IP’s were
run on western blots and probed for Akt, GSK-3, Dvl-3 or the D2DR. The blots were
quantified using the densitometry values as described above.

3.3 RESULTS
3.3.1 Differential effects of haloperidol and clozapine in the PFC and STR
In the PFC, repeated haloperidol or clozapine injections increased the protein levels of
Dvl-3, GSK-3α/β, pGSK-3α/β and β-catenin but not Dvl-1 or Dvl-2 (Figure 3.1a)
consistent with previous results6. Increases in pAkt Thr308 but not pAkt Ser473 or total
Akt were also observed (Figure 3.1b and c).

In the STR, repeated haloperidol

administration increased Dvl-3, GSK-3α/β, pGSK-3α/β and β-catenin but did not affect
Dvl-1 or Dvl-2 protein levels (Figure 3.2a and b). Clozapine treatment increased pGSK-3
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Figure 3.1: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the PFC of rats treated with haloperidol
or clozapine.
(a) Graph of densitometry values for Dvl-1, Dvl-2, Dvl-3, GSK-3α/β, pGSK-3α/β and βcatenin following the treatment of haloperidol, clozapine or an appropriate control. (b)
Representative western blots and (c) graph of densitometry values for Akt, pAkt Ser473
and pAkt Thr308 following the treatment of haloperidol, clozapine or an appropriate
control. For simplicity, the graphs for haloperidol and clozapine are shown using a single
control. Statically significant changes are denoted by the asterisk (p < 0.05, n=8) and
error bars denote the standard error of the mean. For each representative western blot,
the left band represents the vehicle (V) while the right band shows the drug treatment
(D).
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Figure 3.2: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the STR of rats treated with haloperidol
or clozapine.
(a) Representative western blots and (b) graph of densitometry values for Wnt pathway
proteins following the treatment of haloperidol, clozapine or an appropriate control. (c)
Representative western blots and (d) graph of densitometry values for total and
phosphorylated levels of Akt following the treatment of haloperidol, clozapine or an
appropriate control. For each representative western blot, the left band represents the
vehicle (V) while the right band shows the drug treatment (D). For simplicity, the graphs
show a single control for haloperidol and clozapine. The densitometry values are
expressed as a percentage of control with a statistically significance difference denoted
by an asterisk (p < 0.05, mean ± SEM, n=8).
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protein levels but had no effect on Dvl-1, Dvl-2, Dvl-3, GSK-3α/β or β-catenin (Figure
3.2a and b). Increases in pAkt Thr308 protein levels were observed for both
antipsychotics but no change in pAkt Ser473 or total Akt levels were found following
either treatment (Figure 3.2c and d). Collectively, the data revealed that haloperidol and
clozapine had similar effects in the PFC but generated a distinct pattern of change in the
STR.

3.3.2 The effects of mood stabilizers and antidepressants on Akt and the Wnt
pathway
Western blotting revealed that lithium increased pGSK-3α/β but had no effect on
Dvl-1, Dvl-2, Dvl-3, GSK-3α/β or β-catenin in the PFC (Figure 3.3a). In addition, an
increase in pAkt Ser473 was also observed but no change in pAkt Thr308 or total Akt
levels were found (Figure 3.3b). Valproic acid had no effect on Akt or any of the Wnt
pathway proteins tested in the PFC (Figure 3.3a and b). In the STR, lithium upregulated
GSK-3α/β, pGSK-3α/β and β-catenin but had no effect on any of the isoforms of Dvl
(Figure 3.3c). In addition, an increase in pAkt Ser473 protein levels was observed but no
change in Akt and pAkt Thr308 was found (Figure 3.3d). Valproic acid increased pGSK3α/β and pAkt Ser473 levels but had no effect on Dvl, GSK-3α/β, β-catenin Akt or pAkt
Thr308 in the STR (Figure 3.3c and d).
With respect to fluoxetine and imipramine, results from the PFC showed that
fluoxetine and imipramine increased pGSK-3α/β (Figure 3.4a) and pAkt Ser473 levels
only (Figure 3.4b). Identical results were obtained in the STR (Figure 3.4c and d).
Collectively, with the exception of lithium effect’s on β-catenin in the STR, mood
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FIGURE 3.3: Changes in the total protein levels and/or phosphorylation state of
Wnt pathway proteins and Akt in the PFC and STR of rats treated
with lithium or valproic acid.
Graphs of densitometry values for (a) Wnt pathway proteins and (b) total and
phosphorylated Akt in the PFC following lithium and valproic acid treatment. Graphs of
densitometry values for (c) Wnt pathway proteins and (d) total and phosphorylated Akt in
the STR following lithium and valproic acid treatment. The densitometry values are
shown as a percentage of control with a statistical significance denoted by an asterisk
(p<0.05, mean ± SEM, n=8).
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Figure 3.4: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the STR of rats treated with fluoxetine or
imipramine.
Graphs of densitometry values for (a) Wnt pathway proteins and (b) total and
phosphorylated Akt in the PFC of fluoxetine or imipramine treated rats. Graphs of
densitometry values for (c) Wnt pathway proteins and (d) total and phosphorylated Akt in
the STR of fluoxetine or imipramine treated rats. The densitometry values are expressed
as a percentage of control with a statistical significance denoted by the asterisk (p<0.05,
mean ± SEM, n=8).
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stabilizers and antidepressants do not affect the Wnt pathway (i.e β-catenin) but have
overlapping effects on pGSK-3 and pAkt Ser 473.

3.3.3 The association between the D2DR and GSK-3α/β
A recent study showed that Akt and GSK-3α/β are associated with the D2DR in
the PFC of untreated rats6 and that there is an increase in the amount of GSK-3α/β bound
to the D2DR following treatment with the D2DR antagonist, raclopride (chapter 2).
Consequently, co-IP’s were performed to determine if haloperidol or clozapine treatment
alters the association between the D2DR and Akt or D2DR and GSK-3. There were no
alterations in the association between the D2DR complex and Akt following repeated
haloperidol (103.6% ± 14.0, n=6) or clozapine (110.5% ± 8.9, n=6) treatment (Figure 5a
and c, upper panel). Furthermore, the antipsychotic treatments did not affect the total
protein levels of Akt (haloperidol, 120.8% ± 11.1; clozapine, 104.5% ± 8.9, n=6) or
D2DR (haloperidol, 108.5% ± 8.1; clozapine, 115.0% ± 6.4, n=6) (Figure 3.5a and c,
lower panel).

However, both antipsychotics caused an increase in the association

between GSK-3α/β and the D2DR complex, as well as total GSK-3α/β protein levels
(Figure 3.5a and c). The densitometry values showed the increased association between
D2DR and GSK-3α/β was greater than the increase in total GSK-3α/β protein levels,
suggesting there may be an enrichment of GSK-3α/β at the D2DR following haloperidol
(Figure 3.5b) or clozapine (Figure 3.5d).
Given that an association between the D2DR complex and Dvl-3 has been
reported6 and it has been shown that activation of Dvl leads to its translocation to
receptor complexes,21, 22 co-IPs were also performed to determine if the association
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Figure 3.5: Co-IP experiments showing the association between D2DR and Akt,
GSK-3 and/or Dvl-3 in the PFC of haloperidol, clozapine, lithium and
valproic acid treated rats.

Protein samples isolated from the PFC of (a,e) haloperidol (Hal), (b,e) clozapine (Cloz),
(g) lithium (Li) and (i) valproic acid (Val) were immunoprecipitated (IP) with a D2DR
antibody. IP samples were subjected to western blotting (WB) and probed for D2DR, Akt
GSK-3 and/or Dvl-3 (upper panel). WB was performed using the same lysate as the coIPs and probed for D2DR, Akt, GSK-3α/β and/or Dvl-3 (lower panel). Table of the
densitometry values from the co-IPs for D2DR/GSK-3α/β and total GSK-3α/β protein
levels for the (b) haloperidol, (d) clozapine, (h) lithium and (j) valproic acid samples. (f)
Table of the densitometry values from the co-IPs for D2DR/Dvl-3 and total Dvl-3 protein
levels for the haloperidol and clozapine samples. Statistically significant changes are
represented by an asterisk (p < 0.05, mean ± SEM, n=6).
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between the D2DR and Dvl-3 were altered by antipsychotics. The co-IPs revealed an
increased association between Dvl-3 and the D2DR complex that is comparable to the
increase in Dvl-3 protein levels following haloperidol and clozapine treatments (Figure
3.5e and f).

Both lithium and valproic acid were also examined.

There were no

significant changes in the association between the D2DR complex and Akt following
lithium (99.5% ± 8.7, n=6) or valproic acid treatment (96.8% ± 4.8, n=6) (Figure 3.5g
and i, upper panel). No significant changes were detected for total D2DR (lithium,
105.6% ± 10.2; valproic acid 103.4% ± 9.8, n=6) or Akt (lithium, 99.5% ± 8.7; valproic
acid 96.8% ± 4.8, n=6) protein levels following either drug treatments (Figure 3.5g and i,
lower panel).

Furthermore, the association between the D2DR complex and GSK-

3α/β and total GSK-3α/β protein levels were unaffected by lithium (Figure 3.5g and h) or
valproic acid in the PFC (Figure 3.5i and j). Collectively, the results suggest that changes
in the association between GSK-3α/β and the D2DR may be specific to antipsychotics.

3.3.4 The effects of amphetamine on Akt and the Wnt pathway
Repeated amphetamine administration in rodents is frequently used as a partial model of
schizophrenia (Featherstone 2007) and was used in the current study to determine if
changes in Akt and Wnt signalling paralleled those observed in schizophrenia. Repeated
amphetamine treatment caused a decrease in Dvl-3, GSK-3α/β, pGSK-3α/β and βcatenin but did not affect Dvl-1 or Dvl-2 in the PFC (Figure 3.6a and b) and STR (Figure
3.6e). Decreased levels of pAkt Thr308 and pAkt Ser473 were also observed but no
change in total Akt was detected in the PFC (Figure 3.6c and d) and STR (Figure 3.6f).
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Figure 3.6: Changes in the total protein levels and/or phosphorylation state of Wnt
pathway proteins and Akt in the PFC and STR of rats treated with
amphetamine.
(a) Representative western blots and (b) graph of densitometry values of Wnt pathway
proteins following treatment with amphetamine. (c) Representative western blots and (d)
graph of densitometry values of total and phosphorylated Akt in the PFC of amphetamine
treated rats. Graphs of densitometry values of (e) Wnt pathway proteins and (f) total and
phosphorylated Akt in the STR of amphetamine treated rats. For each representative
western blot, the left band represents the vehicle (V) while the right band shows the drug
treatment (D). The densitometry values are expressed as a percentage of control with a
statistically significance difference denoted by an asterisk (p<0.05, mean ± SEM, n=8).
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Co-IPs revealed that repeated amphetamine treatment had no effect on the
association between D2DR and Akt or on total D2DR or Akt protein levels (Figure 3.7a).
A significant decrease in the association between the D2DR and GSK-3α/β and in total
GSK-3α/β protein levels was observed (Figure 3.7a). The decrease in the association
between D2DR and GSK-3α/β was greater than the reduction in total GSK-3α/β protein
levels, suggesting the change in the amount of GSK-3α/β at the D2DR complex is not
due to the reduced GSK-3α/β protein levels alone (Figure 3.7b). Collectively, the results
show that changes in Akt and Wnt signalling in the amphetamine model are functionally
opposite to antipsychotic treatment.

3.4 DISCUSSION
The current study suggests that there may be some important similarities and
differences in GSK-3 signalling between antipsychotics, mood stabilizers and
antidepressants. Only the antipsychotic treatments increased the protein levels of Dvl-3,
β-catenin and pAkt Thr308 in the PFC and/or STR suggesting that antipsychotics activate
Akt and the Wnt pathway in these regions of the brain. In contrast to antipsychotics, the
mood stabilizers and antidepressants increased pAkt Ser473 in the PFC and/or STR.
However, all of the neuropsychiatric drugs induced a similar changes pGSK-3α/β.
The changes on Akt and Wnt signalling induced by the antipsychotic treatments
are consistent with previous studies showing increased pAkt Thr308 levels in haloperidol
treated mice15 and increases in β-catenin, GSK-3α/β and Dvl-3 in the PFC and/or STR of
haloperidol and clozapine treated rats6, 7. Changes in pGSK-3α/β are likely due to the
activation of Akt since it is well established that GSK-3α/β is phosphorylated by Akt16.
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Figure 3.7: Co-IP experiments showing the association of between D2DR and Akt
and GSK-3 in the PFC of rats treated with amphetamine.
(a) Immunoprecipitations (IP) were performed using protein obtained from the PFC of
amphetamine or control treated rats with a D2DR antibody. IP samples were subjected to
western blotting (WB) and probed using an antibody specific for D2DR, Akt or GSK3α/β (upper panels). WB were conducted using the same lysate as the co-IPs and probed
for D2DR, Akt and GSK-3α/β (lower panel). (b) Table of densitometry values from the
co-IPs for D2DR/GSK-3α/β and total GSK-3α/β protein levels. Statistically significant
changes are represented by an asterisk (p<0.05, mean ± SEM, n=6).
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The state of GSK-3α/β activity was unclear since antipsychotics altered both total and
pGSK-3α/β levels.

The reason for the change in total GSK-3α/β protein levels is

unknown, although it is a consistent finding following repeated antipsychotic treatment6,
7

. It is interesting to note, however, that increases in total GSK-3α/β levels parallel

increases in β-catenin. Further experiments will need to be conducted to determine if
there is a link between the two. In addition to changes in Wnt signalling and pAkt
Thr308, antipsychotics also increased the levels of Dvl-3 and GSK-3α/β that are
associated with the D2DR complex. Interestingly, previous studies have shown that
overexpression of Dvl/Dvl-3 is sufficient to activate the Wnt pathway and that following
activation, Dvl translocates to the membrane along with other Wnt signalling proteins21
providing a possible mechanism explaining how GSK-3α/β may be translocated to the
D2DR complex. At this time, the consequence associated with increased levels of GSK-3
or Dvl-3 at the D2DR complex are unclear. However, a recent study showed that GSK-3
interacts with serotonin 1B (5-HT1B) receptor and this interaction could be increased by
activation of the receptor leading to the retention of the receptor at the cell surface23. In
addition, it has been shown that GSK-3 can phosphorylate LRP6, co-receptor for the Wnt
pathway leading to an increase in receptor activation24. Since antipsychotics increase the
translocation of GSK-3 to the D2DR, GSK-3 may induce a functional change at the
receptor. Additional experiments will be required to determine if this is indeed the case.
Several studies including the current one has shown that antipsychotic increase βcatenin levels6, 7, 20. Increased β-catenin levels were also induce by lithium treatment in
the STR, suggesting that β-catenin may not be linked to the clinical effectiveness of
antipsychotics since lithium is not an effective antipsychotic. However, several
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behavioural studies have suggested that β-catenin may be involved in schizophrenia.
Disrupted in schizophrenia-1 (DISC-1), a potential schizophrenia susceptibility gene29,
negatively regulates GSK-3 and stabilizes β-catenin levels30. Mice with DISC-1 loss of
function in the hippocampus showed hyperlocomotion in response to a novel
environment that was normalized by pharmacological inhibition of GSK-3 suggesting
that changes in β-catenin may have rescued the behaviour30. In addition, amphetamineinduced hyperlocomotion is attenuated in β-catenin overexpressing mice31. It has also
been shown that lithium can regulate dopamine-dependent behaviours in mice suggesting
there may be some functional overlap between lithium and D2DR antagonists such as
antipsychotics. Additional experiments will be necessary to understand the role of βcatenin in schizophrenia and antipsychotic drug efficacy.
Mood stabilizers and antidepressants, with the exception of lithium’s effect on βcatenin in the STR, only targeted pGSK-3α/β and pAkt Ser473 in the PFC and/or STR
suggesting these drugs increase Akt activity leading to increased GSK-3α/β
phosphorylation and decreased GSK-3 activity. Increased pGSK-3β and/or pAkt Ser473
have similarly been reported in the frontal cortex of rats or SH-SY5Y cells treated with
mood stabilizers and antidepressants8-11,

25, 26

. Interestingly, antipsychotics increased

pAkt Thr308 whereas mood stabilizers and antidepressants increased pAkt Ser473.
However, it should be noted that a previous study found increased pAkt Ser473 levels in
addition to pAkt Thr308 following haloperidol treatment in mice using a double-dosing
treatment paradigm15. The difference in the phosphorylation state of Akt between
antipsychotics and antidepressants and mood stabilizers may be due to distinct upstream
signalling, since Thr308 and Ser473 are phosphorylated by PDK1 and mTOR,
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respectively.

However, the observation that antidepressants, mood stabilizers and

antipsychotics all target Akt and GSK-3 is intriguing since atypical antipsychotics are
also used to manage the symptoms of major depressive disorder27 either as a
monotherapy or in combination with antidepressants28. Consequently, the findings of the
current study are also consistent with the hypothesis that Akt/GSK-3 signalling may be
involved in mood disorders and depression.
Haloperidol and clozapine are D2DR antagonists although binding of clozapine to
the D2DR is much weaker than haloperidol. The D2DR has been shown to regulate Akt
signalling in mice32 and Dvl-3 is associated with the D2DR6 suggesting that
antipsychotics induce their effects on Akt and Wnt through the D2DR. However, other
receptors may cause or contribute to changes seen following antipsychotic treatment. For
example, the D3DR regulates Akt signalling32 and both haloperidol and clozapine
antagonize the D3DR.

In addition, clozapine’s action at the 5-HT2A receptor may

contribute to the upregulation of pGSK-3 since the blockade of the 5-HT2 receptor has
been shown to increase pGSK-3β levels10. Differences in the receptor binding profiles
between clozapine and haloperidol or the weaker binding of clozapine to the D2DR may
explain why clozapine does not activate the Wnt pathway in the STR but haloperidol
does. Consistent with this notion, a previous study showed that the atypical antipsychotic
risperidone also did not alter GSK-3 or β-catenin in the STR at an atypical dose (low
D2DR binding) but at a higher dose caused increases in β-catenin and GSK-3 similar to
haloperidol7.
Although the antipsychotics, mood stabilizers and antidepressants that were tested
caused an increases in pGSK-3 and pAkt, these different neuropsychiatric treatments
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induce these changes by different mechanisms. In contrast to antipsychotics, fluoxetine
and imipramine likely cause increases in pAkt and pGSK-3 through serotonin receptors10.
Lithium has been shown to dose dependently inhibit GSK-38, 33 directly and indirectly
through activation of Akt34, 35. Valproic acid also inhibits GSK-3 activity, although the
precise mechanism is less clear. An in vitro study using SH-SY5Y cells attributed the
increase in pAkt and pGSK-3 to the inhibition of histone deacetylase by valproic acid26.
Changes in neurochemistry and behavior following repeated amphetamine
treatment have been reported to parallel some of the abnormalities found in patients with
schizophrenia36. Consequently, Akt and Wnt were investigated in rats following repeated
treatment with amphetamine. Reductions in pAkt, GSK-3, pGSK-3, Dvl-3 and β-catenin
were noted, consistent with previous reports for β-catenin and GSK-3 in the ventral
midbrain20 and pAkt in the striatum37, 38. The changes observed following amphetamine
treatment are opposite to those observed following antipsychotic treatment. In addition,
alterations in the Akt and Wnt pathways found in the amphetamine model parallels
changes reported in schizophrenia. Reductions in GSK-3β and pGSK-3β protein levels
and β-catenin staining has been reported in the frontal cortex and hippocampus of
schizophrenia postmortem brains respectively1, 2, 15, 39. Reductions in Akt-1 protein levels
have also been reported in the frontal cortex of schizophrenic patients15. Although,
amphetamine did not affect total Akt protein levels, the reduction in pAkt functionally
parallels the changes observed in the postmortem study. Thus, amphetamine treatment
may provide a useful model for further studying the role of Akt and Wnt in schizophrenia
and the potential therapeutic value of drugs that target Akt and Wnt.
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CHAPTER FOUR
Regulation of Akt and Wnt signalling by the group II metabotropic glutamate
receptor antagonist LY341495 and agonist LY379268
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4.1 INTRODUCTION
Converging lines of research have implicated Group II metabotropic glutamate
receptors (mGluR2 and mGluR3) in schizophrenia and as a potential new therapeutic
target to treat the symptoms of schizophrenia.

MGluR2/3 are G-protein coupled

receptors and are highly expressed in regions of the brain associated with schizophrenia
including the prefrontal cortex and striatum1, 2. MGluR3 has been identified as a possible
schizophrenia susceptibility gene3,

4

and a decrease in the dimer form of mGluR3 has

been reported in the prefrontal cortex of schizophrenic patients5. Animal studies have
shown that mGluR2/3 antagonists LY341495 and LY366457 increase locomotor activity
and that the increase in activity can be attenuated by treatment with antipsychotics6, 7.
Animal studies have also demonstrated that mGluR2/3 agonists may be effective
antipsychotics.

Treatment with the mGluR2/3 agonists, LY379268 and LY354740

attenuated phencyclidine (PCP) and/or amphetamine induced hyperlocomotor activity8, 9.
Finally, a phase 2 clinical trial has shown that the mGluR2/3 agonist, LY2140023 may be
effective for alleviating the positive and negative symptoms of schizophrenia in human
patients10. However, while there is evidence to suggest that mGluR2/3 may be involved
in schizophrenia, the molecular mechanism responsible for mediating the effects of
mGluR2/3 agonists/antagonists have not been established.
GSK-3 is regulated by Akt and the Wnt pathway and both signalling pathways
have been implicated in schizophrenia and antipsychotic drug action. Akt-1, Frizzled-3,
Wnt-1 and GSK-3 have all been identified as possible schizophrenia susceptibility genes
and/or have been shown to have altered protein levels in postmortem studies11-16. Animal
studies using models such as amphetamine-sensitization, the DAT-KO mouse and PCP
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show changes in GSK-3 and/or Akt phosphorylation16-20.

In addition, changes in total

and/or phosphorylated Akt, GSK-3 and Wnt pathway proteins have also been reported
following repeated treatment with typical or atypical antipsychotics16, 21-23.
Since mGluR2/3 agonists may exhibit antipsychotic properties, it is possible that
there is overlap in the signalling pathways targeted by traditional antipsychotics and
mGluR2/3 agonists. Consequently, the purpose of the current study was to determine if
mGluR2/3 regulates Akt and/or Wnt signalling in the PFC and STR following acute and
repeated administration of the mGluR2/3 agonist LY379268 and mGluR2/3 antagonist
LY341495. In addition, since inhibition of GSK-3 is implicated in antipsychotic drug
action, locomotor studies were performed to examine the effects of GSK-3 inhibition on
increased locomotor activity induced by LY341495.

4.2 MATERIALS AND METHODS
4.2.1 Drug Paradigm
Adult male Spraque Dawley rats 14+ weeks of age (Charles River) were housed in pairs
in a 12 hour light/dark cycle with free access to food and water. Rats were treated with
the mGluR2/3 agonist LY379268 (1.0 mg/kg or 3.0 mg/kg, i.p., Tocris Bioscience),
mGluR2/3 receptor antagonist LY341495 (1.0 mg/kg or 3.0 mg/kg, i.p., Tocris
Bioscience) or vehicle (n=8 rats/treatment) once or daily for 7 days. Doses were selected
based on behavioural studies that assessed the ability of LY379268 or LY341495 to
attenuate PCP induced hyperlocomotion8 or increase locomotor activity respectively7.
Protein was isolated from the PFC and STR of rats following either acute or repeated
treatment. Every effort was made to minimize pain and suffering and reduce the number
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of rats used in the experiments. All experiments were conducted in accordance with the
Canadian Council on Animal Care.

4.2.2 Western blotting
Protein isolation, quantification and western blotting were performed as previously
described for the PFC and STR22. Densitometry values were obtained from X-ray film
using a grey scale calibrated scanner (Epson) and Kodak Molecular Imaging software.
Densitometry values were corrected for α-tubulin and expressed as a percentage of
control. Data was analyzed for statistical significance using a Student’s t-test. The
source and dilution of the antibodies were as follows Akt (Cell Signalling Technology,
1:1250), phospho-Akt Ser473 (Cell Signalling Technology, 1:1000), phospho-Akt
Thr308 (Millipore, 1:1000), Dvl-1 (Santa Cruz Biotechnology, 1:100), Dvl-2 (Chemicon,
1:1000), Dvl-3 (Santa Cruz Biotechnology, 1:100), GSK-3 (Santa Cruz Biotechnology,
1:300), phospho-GSK-3 (Cell Signalling Technology, 1:1000), β-catenin (Sigma-Aldrich,
1:20000) and α-tubulin (Sigma-Aldrich, 1:120000).

4.2.3 Co-Immunoprecipitations
Protein was isolated from the PFC of drug naïve rats or from the PFC and/or STR of
LY379268 (3 mg/kg), raclopride (1 mg/kg) or clozapine (25 mg/kg) treated rats using a
non-denaturing lysis buffer with the addition of protease (Complete Mini, Roche
Diagnostic) and phosphatase (Cocktail Set 2, Sigma-Adrich; Cocktail Set IV,
Calbiochem) inhibitors (n=6 rats/treatment). Immunoprecipitations (IPs) were performed
using the ExactCruz system (SantaCruz Biotechnology), 500μg of protein and antibodies
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for the mGluR2/3(4 μg/IP, Millipore) or D2DR (3 μg/IP, Santa Cruz Biotechnology) as
outlined previously23. Negative controls were performed using a non-specific IgG (Santa
Cruz Biotechnology) from the same species in place of the IP antibody. The IP samples
were subjected to western blotting (WB) and probed for the protein of interest; Dvl-2
(Santa Cruz Biotechnology, 1:100), Dvl-3 (Santa Cruz Biotechnology, 1:100), GSK-3
(Santa Cruz Biotechnology, 1:300) Akt (Cell Signalling Technology, 1:1250).

4.2.4 Locomotor activity
Horizontal locomotor activity was recorded from rats treated with LY341495 (1.0 mg/kg
and 3.0 mg/kg, i.p.) or an appropriate vehicle following a single injection or following 7
consecutive daily injections (n=12 rats/treatment). In a separate set of experiments, rats
were treated once or daily for 7 consecutive days with LY341495 (3.0 mg/kg, i.p.) or
vehicle followed 5 minutes later by the administration of the GSK-3 inhibitor, SB216763
(3.0 mg/kg, i.p.) or vehicle (n=16 rats/treatment). Horizontal locomotor activity was
recorded on day 1 and day 7. The dose of SB216763 was selected based on previous
studies showing that it attenuated amphetamine-induced hyperlocomotion at 3.0mg/kg.
Horizontal locomotor activity was recorded using Med Associates activity monitor
chambers and software for 60 minutes. Data was analyzed using a one-way ANOVA or
two-way ANOVA followed by the Newman-Keuls post hoc test.
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4.3 RESULTS
4.3.1 The effects of mGluR2/3 agonism (LY379268) on Akt and Wnt pathway
proteins
A preclinical animal study suggested that mGluR2/3 agonists possess
antipsychotic-like properties10 and Wnt pathway proteins and Akt have been implicated
in schizophrenia and antipsychotic drug action16,

24

. Consequently, Akt and proteins

involved in Wnt signalling were assessed in the PFC and STR following repeated
administration of the mGluR2/3 agonist, LY379268 to determine if LY379268 targets
Wnt pathway proteins and/or Akt. At 3.0mg/kg, LY379268 increased Dvl-2, Dvl-3,
GSK-3α/β, pGSK-3α/β and β-catenin protein levels in the PFC and STR (Figure 4.1a
and b). Increases in pAkt Thr308 and pAkt Ser473 were also observed in both the STR
and PFC following LY379268 treatment (Figure 4.1c and d). However, at a lower dose
of LY379268 (1.0 mg/kg), no significant changes in any of the Wnt pathway proteins
(Figure 4.1e) or in total and phosphorylated Akt levels were found in the PFC or STR
(Figure 4.1f).
Previous studies have shown that changes in the Wnt pathway are observed
following repeated but not acute administration of antipsychotics22 consistent with the
clinical observation that antipsychotics requires repeated treatment to exert their
beneficial effects. To determine if this is also true for LY379268, rats were treated
acutely with LY379268 and the effects on Akt and the Wnt pathway were assessed. The
higher dose was chosen since changes following repeated administration of LY379268
were only observed following 3.0 mg/kg. Acute administration of LY379268 resulted in
increased phosphorylation of GSK-3α/β but did not effect Dvl, GSK-3α/β or β-catenin in
the PFC and STR (Figure 4.2a and b). Increased pAkt Ser473 was also detected but no
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Figure 4.1: The effects of repeated administration of LY379268 on Wnt pathway
proteins and Akt.
(a) Representative western blots and (b) graph of densitometry values for Wnt pathway
proteins in the PFC and STR of rats treated with 3.0mg/kg LY379268. (c) Representative
western blots and (d) graph of densitometry values for total and phosphorylated Akt in
the PFC and STR of rats treated with 3.0mg/kg LY379268. Graphs of densitometry
values for (e) Wnt pathway proteins and (f) total and phosphorylated Akt in the PFC and
STR of rats treated with 1.0mg/kg LY379268. For each representative western blot, the
left band represents the vehicle (V) while the right band shows the drug treatment (D).
The densitometry values are expressed as a percentage of control with a statistically
significance difference denoted by an asterisk (p < 0.05, mean ± SEM, n=8).
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Figure 4.2: The effects of acute administration of LY379268 on Wnt pathway
proteins and Akt.
(a) Representative western blots and (b) graph of densitometry values for Wnt pathway
proteins in the PFC and STR of rats treated with 3.0mg/kg LY379268. (c) Representative
western blots and (d) graph of densitometry values for total and phosphorylated Akt in
the PFC and STR of rats treated with 3.0mg/kg LY379268. For each representative
western blot, the left band represents the vehicle (V) while the right band shows the drug
treatment (D). The densitometry values are expressed as a percentage of control with a
statistically significance difference denoted by an asterisk (p < 0.05, mean ± SEM, n=8).
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changes in pAkt Thr308 or total Akt levels were observed in the PFC and STR (Figure
4.2c and d). Therefore, acute administration altered the phosphorylation of Akt and GSK3α/β but only repeated administration of LY379268 had an effect on total protein levels
including changes in β-catenin.

4.3.2 The effects of mGluR2/3 antagonism (LY341495) on Akt and Wnt pathway
proteins
The mGluR2/3 antagonist LY341495 was used to examine the effects of blocking
the mGluR2/3 on Akt and Wnt pathway proteins. Repeated treatment with 3.0mg/kg of
LY341495 decreased Dvl-2, pGSK-3α/β and β-catenin protein levels but Dvl-1, Dvl-3
and GSK-3α/β were unaffected in both the PFC and STR (Figure 4.3a and b).

In

addition, to changes in the Wnt proteins, a reduction in pAkt Ser473 but not in total Akt
or pAkt Thr308 were observed in the PFC and STR (Figure 4.3c and d). A lower dose of
repeated LY341495 (1.0 mg/kg) was also used and had no effect on any of the proteins of
interest in the PFC or STR (Figure 4.3e). Finally, changes in Akt and Wnt pathway
protein were assessed following acute administration of LY341495. Decreases in pGSK3α/β (Figure 4.4a and b) and pAkt Ser473 (Figure 4.4c and d) were observed in the PFC
and STR following acute administration of LY341495 (3.0 mg/kg). Therefore, acute
administration of LY341495 decreased pAkt and pGSK-3 levels but repeated treatment
(3.0mg/kg) is needed to reduce β-catenin levels. Furthermore, LY341495 had generally
the opposite effect following acute and chronic administration compared to mGluR2/3
agonist, LY379268.
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Figure 4.3: The effects of repeated administration of LY341495 on Wnt pathway
proteins and Akt.
(a) Representative western blots and (b) graph of densitometry values for Wnt pathway
proteins in the PFC and STR of rats treated with 3.0mg/kg LY341495. (c) Representative
western blots and (d) graph of densitometry values for total and phosphorylated Akt in
the PFC and STR of rats treated with 3.0mg/kg LY341495. (e) Graph of densitometry
values for Wnt pathway proteins in the PFC and STR of rats treated with 1.0mg/kg
LY341495. For each representative western blot, the left band represents the vehicle (V)
while the right band shows the drug treatment (D). The densitometry values are
expressed as a percentage of control with a statistically significance difference denoted
by an asterisk (p < 0.05, mean ± SEM, n=8).
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Figure 4.4: The effects of acute administration of LY341495 on Wnt pathway
proteins and Akt.
(a) Representative blots and (b) graph of densitometry values for Wnt pathway proteins
in the PFC and STR of rats treated acutely with 3.0mg/kg LY341495. (c) Representative
blots and (d) graph of densitometry values for total and phosphorylated Akt in the PFC
and STR of rats treated acutely with 3.0 mg/kg LY341495. For each representative
western blot, the left band represents the vehicle (V) while the right band shows the drug
treatment (D). The densitometry values are expressed as a percentage of control with a
statistically significance difference denoted by an asterisk (p < 0.05, mean ± SEM, n=8).
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4.3.3 Interactions between mGluR2/3 and Akt and Wnt pathway proteins
Treatment with LY341495 or LY379268 affected both Akt and Wnt pathway
proteins but how these events occur is unclear. Associations between Akt and Dvl-3 and
the D2DR complex have previously been reported23 and thus co-IP experiments were
conducted to determine if there is also an association between the mGluR2/3 complex
and Dvl, GSK-3 and/or Akt. Co-IPs revealed a weak association between mGluR2/3 and
Dvl-2 in the PFC of drug naïve rats (Figure 4.5a), whereas no association was found
between the mGluR2/3 and Dvl-3 (Figure 4.5b). Furthermore, the co-IPs suggest there is
no association between mGluR2/3 and GSK-3α/β (Figure 4.5b) or Akt (Figure 4.5c).
Activation of the Wnt pathway has been shown to cause the translocation of Dvl
and GSK-3 to receptor complexes. Since repeated LY379268 treatment activates the
Wnt pathway, co-IP’s were performed using protein isolated from the PFC of LY379268
treated rats, to determine if there is a translocation of Dvl-2, GSK-3 and/or Akt to the
mGluR2/3 complex. In the PFC, co-IPs showed an increased association between the
mGluR2/3 and Dvl-2 and GSK-3α/β but not with Akt following repeated LY379268
treatment (Figure 4.5d). Since activation of the Wnt pathway was also seen in the STR,
the association between mGluR2/3 and GSK-3 was also assessed in the STR.

A

translocation of GSK-3α/β to the mGluR2/3 complex in the STR was observed following
LY379268 treatment (Figure 4.5e). The results show that LY379268 can induce changes
in Akt and Wnt proteins as well as alter the association between the mGluR2/3 complex
and Dvl-2 and GSK-3α/β.
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Figure 4.5: Co-Immunoprecipitation experiments showing association between
mGluR2/3 and Wnt pathway proteins and/or Akt in drug naïve rats or
following LY379268 treatment.
Protein samples obtained from the PFC of drug naïve rats were immunoprecipitated (IP)
with a mGluR2/3 antibody. IP samples were subjected to western blotting (WB) and
probed for (a) Dvl-2, Dvl-3, (b) GSK-3 and (c) Akt (+ lanes). For the negative control
lanes, co-IPs were conducted using a non-specific IgG in place of the IP antibody (lanes). Protein samples obtained from the (d) PFC and (e) STR of LY379268 treated rats
were IP with a mGluR2/3 antibody. IP samples were subjected to WB and probed for
Dvl-2, GSK-3 and/or Akt. Protein samples obtained from (f) the PFC and STR of
LY379268 treated rats were IP with a D2DR antibody. IP samples were subjected to WB
and probed for GSK-3. (g) IP samples isolated from the PFC of raclopride and clozapine
treated rats were IP with a mGluR2/3 antibody. IP samples were subjected to WB and
probed for GSK-3.
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Increased association of GSK-3α/β and the D2DR complex has been observed in
the PFC following repeated treatment with the antipsychotics haloperidol and clozapine
(chapter 3) and with D2DR antagonist raclopride (chapter 3). Given that mGluR2/3
agonists may affect extracellular dopamine levels25,

26

, the study investigated whether

LY379268 altered the association between the D2DR and GSK-3α/β.

The co-IPs

revealed that LY379268 increased the association of GSK-3α/β and D2DR complex in
the PFC and STR (Figure 4.5f) in addition to the mGluR2/3. In addition, since D2DR
antagonists can affect the translocation of GSK-3 (chapter 2 and 3), raclopride (D2DR
antagonist) and clozapine (atypical antipsychotic) were examined to determine if they are
able to alter the association of GSK-3α/β at the mGluR2/3 complex. Neither raclopride
nor clozapine altered the association between mGluR2/3 and GSK-3α/β in the PFC
(Figure 4.5g). The results suggest that changes at the mGluR2/3 induced by LY379268
were due to mGluR2/3 signalling and not the indirect effects of dopamine/D2DR
signalling. Finally, LY379268, clozapine and raclopride increased GSK-3 protein levels,
as previously reported but did not effect mGluR2/3 protein levels (data not shown).

4.3.4 Effects of LY341495 on locomotion
Previous studies have demonstrated that acute administration of LY341495 dose
dependently increased locomotor activity in mice7. Given that acute and repeated
LY341495 treatment had different effects on Wnt signalling, we assessed horizontal
locomotor activity following both acute and repeated administration of LY341495.
Consistent with previous studies, Figure 4.6a shows increased horizontal activity was
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Figure 4.6:

Total horizontal locomotor activity for rats treated acutely or
repeatedly with LY341495 or LY341495 and SB216763.

(a) Total horizontal locomotor activity for rats acutely and repeatedly treated with
1.0mg/kg and 3.0 mg/kg LY341495. A statistical significance is denoted by and asterisk
as compared to the control (n=12, mean ± SEM, p<0.05). Total horizontal locomotor
activity for rats (b) acutely and (c) repeatedly treated with LY341495 (3.0mg/kg) and
administered SB216763 (3.0 mg/kg). Statistical significance is denoted by a difference in
lettering (n=16, mean ± SEM, p<0.05). (Control, Cont; LY341495, LY; SB216763, SB)
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observed following acute treatment with 3.0 mg/kg of LY341495 but not at a lower dose
of 1.0 mg/kg. Repeated treatment with LY341495 also increased horizontal activity at a
dose of 3.0 mg/kg but not at 1.0 mg/kg (Figure 4.6a). Overall, similar changes in total
horizontal activity were observed following acute and repeated LY341495 treatment
(3.0mg/kg).
A previous study has implicated GSK-3 signalling in attenuating hyperlocomotion
in dopamine-transporter knockout mice27. Therefore, the GSK-3 inhibitor SB216763 was
used to determine if inhibiting GSK-3 could attenuate the increase in locomotion
observed following acute and repeated treatment of LY341495. Results showed that
SB216763 significantly attenuated the increase in horizontal activity following acute
administration of LY341495 (Figure 4.6b). In addition, the effects of repeated SB216763
decreased horizontal activity induced by daily administration of LY341495 (Figure 4.6c).
Overall, acute and repeated co-administration of SB216763 in LY341495 had similar
effects on locomotion.

4.4 DISCUSSION
4.4.1 mGluR2/3 mediates changes in Wnt and Akt signalling
The current study demonstrated that the mGluR2/3 causes changes in Akt and the
Wnt pathway. Repeated administration of LY379268 (mGluR2/3 agonist) activated the
Wnt pathway leading to the stabilization of β-catenin and also activated Akt. Repeated
LY341495 (mGluR2/3 antagonist) treatment induced a similar but inverse response
compared to LY379268, including a decrease in β-catenin protein levels and a reduction
of pAkt. Acute treatment of LY379268 or LY341495, in contrast, induced changes in the

146
phosphorylation state of Akt and GSK-3 but had no effect on total protein levels or the
transcription factor β-catenin.
The link between mGluR2/3 and Akt and Wnt signalling is unclear, although the
association between Dvl-2 and the mGluR2/3 complex provides a potential mechanism to
explain how mGluR2/3 exerts its affect on the Wnt pathway.

Consistent with this

hypothesis, a previous study has shown that increased Dvl-2 levels results in
translocation of Dvl-2 to the plasma membrane, a necessary step for β-catenin
stabilization28. Thus, upregulation of Dvl-2 may induce the translocation of Dvl-2 to the
mGluR2/3 observed following repeated LY379268 treatment. In addition, Dvl-2 may be
responsible for the recruitment of GSK-3 to the mGluR2/3 since previous studies have
shown that Dvl-2 recruits Wnt pathway proteins such as Axin to the plasma membrane28.
Finally, overexpression of Dvl-2 in Neuro 2A cells has been shown to be sufficient to
stabilize β-catenin and increase TCF mediated gene transcription, consistent with the
increased levels of β-catenin observed after LY379268 treatment29. Collectively, the
results of the Dvl-2 studies parallel the changes observed following LY379268 treatment
and suggest that changes in Dvl-2 levels induced by mGluR2/3 agonism or antagonism
may be responsible for changes in Wnt signalling observed following repeated treatment
of LY379268 and LY341495.
GSK-3 is a major target of Akt30, 31 and changes in the phosphorylation state of
Akt following LY379268 or LY341495 likely account for the change in GSK-3
phosphorylation. However, it is unknown how mGluR2/3 signalling regulates the AktGSK-3 cascade given there is no association between Akt and the mGluR2/3 complex in
either the drug naïve rats or following LY379268 treatment. This suggests Akt signalling
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may not be affected by the mGluR2/3 directly. Several studies have shown that the
phosphorylation state of Akt and consequently GSK-3 is regulated by the D2DR/D3DR 32
and mGluR2/3 have been shown to modify dopamine release25, 33, 34. Alternatively, it has
been suggested that LY379268 has a significant affinity for the D2DR and may function
as a partial dopamine agonist35,

36

, although a separate study failed to show a direct

interaction between D2DR and LY37926837. Therefore, changes in D2DR/D3DR and not
mGluR2/3 signalling may be responsible for the regulation of the Akt-GSK-3 cascade
following treatment with LY379268 and LY341495.

In support of this hypothesis,

LY379268 also caused an increased association between GSK-3 and the D2DR complex.
Increased association between GSK-3 and the D2DR complex has been observed
following raclopride, haloperidol and clozapine treatment (chapter 2 and 3), suggesting
that GSK-3 and D2DR interactions are regulated by D2DR signalling.

In addition,

alterations in D2DR signalling may explain the increase in Dvl-3 protein levels observed
following repeated LY379268 treatment since it has been shown that D2DR may regulate
Dvl-3 levels (chapter 2).
While D2DR signalling may be responsible for pAkt, pGSK-3 and Dvl-3 levels,
the changes in Dvl-2 protein levels and at the mGluR2/3 complex can’t be attributed to
dopamine signalling. Changes in Dvl-2 protein levels were induced by LY379268 and
LY341495 but not by raclopride, antipsychotics or amphetamine22,

23

.

In addition,

translocation of GSK-3 to the mGluR2/3 was induced by LY379268 but not by repeated
raclopride or clozapine treatments. Overall, LY379268 and LY341495 may mediate
changes associated with Dvl-2 via the mGluR2/3, whereas changes in Akt and Dvl-3 may
be mediated by D2DR.
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4.4.2 LY341495 and Behavior
The increase in horizontal activity observed following LY341495 administration
is consistent with previous studies showing that acute treatment of LY341495 dose
dependently increased locomotor activity7,

38

. The changes in the locomotor activity

correlated to the alterations in the phosphorylation state of Akt and GSK3α/β. Decreases in pGSK-3 α/β and pAkt Ser473 and increased locomotor activity were
observed following 3.0mg/kg and not following 1.0mg/kg of LY341495 treatment.
It has been suggested that increased locomotion induced by LY341495 is due to
impairments in the ability of the rat to habituate to its surrounding and may be relevant to
the cognitive impairments of schizophrenia6. It is important to note that the effects of
LY341495 on locomotor activity differs from amphetamine, since LY341495 does not
induce hyperlocomotion6. Thus, LY341495 and amphetamine induced locomotion
involve different mechanisms. Both LY341495 and amphetamine treatments mediate
changes in Akt and Wnt signalling. However, there are differences in Wnt signalling as
amphetamine decreases Dvl-3 and GSK-3 protein levels (chapter three) and LY341495
decreased Dvl-2 and had no effect on GSK-3.

Both repeated administration of

LY341495 and amphetamine induce similar changes, including reductions in pAkt,
pGSK-3 and β-catenin protein levels. Overall, LY341495 and amphetamine induce
distinct but overlapping changes in Akt and Wnt signalling.
Studies have shown that the inhibition of GSK-3 normalizes hyperlocomotion in
amphetamine-sensitized rats and hyperdopaminergic DAT-KO mice27 suggesting that
GSK-3 plays an important role in hyperlocomotion.

Administration of LY379268,

clozapine, haloperidol and risperidone, have all been shown to reverse LY341495
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induced increases in locomotor activity6. All of these compounds have similar effects on
GSK-321,

22

, suggesting that GSK-3 may also be involved in mGluR2/3 induced

locomotor activity. Consistent with this hypothesis, inhibition of GSK-3 with SB216763
attenuated LY341495 induced increases in locomotion.

Interestingly, attenuation of

locomotion by SB216763 was observed following both acute and repeated treatment.
Acute administration of LY341495 only affected pAkt and pGSK-3 suggesting that
changes in total protein levels of GSK-3, Dvl and β-catenin may not be important for
mGluR2/3 mediated locomotor activity. However, other animal models have suggested
that β-catenin may be important for hyperlocomotor activity. For example, amphetamineinduced hyperlocomotion is inhibited in transgenic mice overexpressing β-catenin39.
Disrupted-in-schizophrenia-1 (DISC-1) interacts directly with GSK-3 and regulates βcatenin stabilization. DISC-1 knockout mice exhibit hyperlocomotion that is normalized
by SB216763 treatment40. Thus, the data suggests that different downstream targets of
GSK-3 may regulate LY341495-induced versus amphetamine-induced increases in
locomotor activity.

4.4.3 Comparison of LY379268 with antipsychotics
A phase 2 clinical trial suggested that the mGluR2/3 agonist, LY2140023 can
alleviate the positive symptoms of schizophrenia and may represent an alterative to
traditional antipsychotic drugs for the treatment of schizophrenia10. Interestingly, the
mGluR2/3 agonist, LY379268 and antipsychotic drugs both target Akt and Wnt
signalling. In addition, translocation of GSK-3 to the D2DR complex has also been
observed following LY379268, haloperidol and clozapine treatments23. However, there
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are also important differences. The D2DR is associated with Dvl-3, Akt and GSK-3
whereas the mGluR2/3 is associated with Dvl-2 and GSK-3 following treatment with
LY379268. In addition, LY379268 altered levels of Dvl-2, whereas antipsychotic
treatment affected Dvl-323. Dvl-2 may activate different signalling pathways compared
to Dvl-3. For example previous in vitro studies have shown that the overexpression of
Dvl-2 activates JNK41. Overexpression of Dvl-3 in PC12 or SH-SY5Y cells in vitro or
upregulation of Dvl-3 by antipsychotics in vivo does not effect JNK signalling23.
Although there are differences in Wnt signalling, the overall pattern of change generated
by LY379268 and antipsychotics is similar. Therefore, Akt and/or the Wnt pathway may
be important for some of the therapeutic benefits of antipsychotics and mGluR2/3
agonists and may represent new targets for the development of drugs to treat
schizophrenia.
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5.1 SUMMARY OF RESULTS AND CONCLUSIONS
5.1.1

Alterations in GSK-3 and Akt signalling induced by the dopamine D2
receptor are mediated by Dvl-3
Chapter two demonstrated that D2DR regulation of Akt and Wnt signalling is

mediated by Dvl-3. The results showed that raclopride (D2DR antagonist) increased the
levels of specific proteins associated with Akt and the Wnt pathway in a pattern identical
to what we previously reported following antipsychotic treatment1-3.

In addition,

raclopride induced the translocation of GSK-3 to the D2DR complex. In vitro studies
showed that overexpression of Dvl-3 induced changes in Akt and Wnt signalling identical
to what was observed in vivo following raclopride and antipsychotic treatments
suggesting that raclopride and antipsychotics regulate Akt and the Wnt pathway via Dvl3. Neither SCH23390 (D1DR antagonist) nor nafadotride (D3DR antagonist) affected
Wnt pathway proteins, although nafadotride altered the phosphorylation state of Akt and
GSK-3. This key difference in Wnt signalling may explain why drugs that target D1DR
and D3DR fail to alleviate psychosis but D2DR antagonism is critical. The study also
showed that alterations in Akt and Wnt signalling induced by quinpirole (D2DR agonist)
were consistent with findings from genetic and post-mortem schizophrenia studies and
from animal models of schizophrenia such as the DAT-KO mouse and amphetaminesensitization.

Given the potential involvement of Akt and Wnt pathways in the

manifestation of schizophrenia and the findings of the current study concerning Dvl-3 as
the trigger for the observed cascade of changes, an investigation (post-mortem and
genetic) of Dvl-3 in schizophrenia might be of particular interest.
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5.1.2 The effects of neuropsychiatric drugs and amphetamine on GSK- 3 signalling
Chapter three identified key differences in GSK-3 signalling that were induced
by antipsychotics but not by mood stabilizers or antidepressants. It has found that
haloperidol and clozapine induced a common and specific response in Wnt signalling that
was not mimicked by the mood stabilizers and antidepressants tested.

The unique

antipsychotic response provides additional evidence that the Wnt pathway may be
important for antipsychotic drug action. In contrast to Wnt, similar changes in pAkt and
pGSK-3 were observed following antipsychotic, mood stabilizer and antidepressant
treatments. This is an interesting observation given the overlap between antipsychotics,
mood stabilizers and antidepressants in treating bipolar disorder and major depressive
disorder, respectively. In particular, atypical antipsychotics have been shown to be
effective in the treatment of bipolar depression (depressive phase of bipolar disorder)4
and major depressive disorder5.
The study also found that amphetamine-sensitization, a putative model for the
positive symptoms of schizophrenia induced the opposite response on Akt and Wnt
signalling as the antipsychotic treatments. Furthermore, the changes in these pathways
were functionally consistent with abnormalities observed in post-mortem studies using
brains of schizophrenic patients. Thus, it is hypothesized that the regulation of the Wnt
pathway by antipsychotics may compensate for abnormalities found in schizophrenia
leading to behavioural changes.

Therefore, targeting the Wnt pathway, Dvl-3 in

particular, may be of interest for pharmaceutical intervention for the positive symptoms
of schizophrenia.
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5.1.3 Regulation of Akt and Wnt signalling by the group II metabotropic glutamate
receptor agonist LY379268 and antagonist LY341495
Chapter four examined the relationship between mGluR2/3 and Akt and Wnt
signalling, since mGluR3 have been associated with schizophrenia6 and mGluR2/3
agonists may have antipsychotic-like effects7. The study showed that administration of
the mGluR2/3 agonist, LY379268 and mGluR2/3 antagonist, LY341495 induced
opposite responses on Akt and Wnt signalling. The association between Dvl-2 and
mGluR2/3 complex revealed a potential mechanism that may explain how
LY379268/LY341495 regulates the Wnt pathway. In addition, the results also showed
there was no association between Akt and mGluR2/3 suggesting that changes in Akt
signalling induced by LY379268/LY341495 are not directly regulated by the mGluR2/3.
Instead, the data suggest that LY379268/LY341495 direct or indirect effects on the D2DR
are responsible for the changes observed in Akt signalling.

Overall, the study

demonstrates that LY379268 and LY341495 likely mediate their changes on Wnt and
Akt signalling through the mGluR2/3 and D2DR.
In conclusion, one of the most striking findings of the thesis is that LY379268,
haloperidol and clozapine mediate similar changes on Akt and Wnt signalling, including
increases in pAkt and β-catenin protein levels. The results suggest these signalling
cascades may be involved in the therapeutic effects of antipsychotics and mGluR2/3
agonists and may represent a potential target for the development of pharmaceuticals.

5.2 DISCUSSION
Although antipsychotic have been prescribed since the 1950s, the molecular
mechanism(s) involved in their ability to alleviate psychosis remains elusive. It is known

159
that the blockade of the D2DR is critical for the ability of antipsychotics to alleviate
psychosis8 but beyond D2DR antagonism the molecular mechanisms are unclear. Known
D2DR signalling pathways, such as MAPK, PKA and PKC have provided no persuasive
evidence for their involvement in antipsychotic drug action9-11. Recently, our laboratory
and others have reported new signalling pathways associated with antipsychotics and
schizophrenia involving Akt, GSK-3 and Wnt1-3, 12. Given the possible involvement of
Akt and Wnt signalling in schizophrenia, the thesis examined the role of Akt and Wnt
signalling in drugs that alleviate psychosis and in animal models of schizophrenia.
Collectively, the studies showed that drugs that alleviate psychosis induce a common and
specific pattern of change in Wnt signalling. Thus, it is proposed that antipsychotics and
mGluR2/3 agonists ability to alleviate psychosis may be mediated by the Wnt pathway.
Based on the conclusions from this thesis and previous studies a working
hypothesis has been developed to explain how antipsychotics and mGluR2/3 agonists
may regulate Akt and Wnt signalling (Figure 5.1). Antipsychotic drugs and mGluR2/3
agonists cause an increase in Dvl protein levels leading to functional changes at the
respective receptor complexes, activation of Akt and the stabilization of β-catenin levels.
More specifically, antipsychotics cause an increase in Dvl-3 protein levels leading to the
translocation of Dvl-3 and GSK-3 to the D2DR complex.

LY379268 activates the

mGluR2/3 resulting in an upregulation of Dvl-2 protein levels, which leads to the
recruitment of Dvl-2 and GSK-3 to the mGluR2/3 complex. In addition to its effects at
the mGluR2/3, LY379268 also effects D2DR signalling either directly by binding to the
D2DR13 or indirectly by influencing extracellular DA levels14, 15. LY379268 effects on
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Figure 5.1: Working model of antipsychotics and mGluR2/3 agonist regulation of
Akt and Wnt signalling.
A) Resting State Resting State: In a native state, Dvl-3 and Akt are associated with
the D2DR complex but there is no association between Dvl or Akt and the mGluR2/3
complex. A “phosphorylation complex” involving glycogen synthase kinase-3 (GSK3), Axin and adenomatous polyposis coli (APC) facilitates the phosphorylation of βcatenin by GSK-3. Phosphorylated β-catenin is targeted for ubiquitin-mediated
degradation.
B) Antipsychotic or mGluR2/3 agonist treatment: Haloperidol or clozapine bind to
and antagonize the D2DR resulting in an upregulation of Dvl-3 protein levels. An
increase in Dvl-3 levels leads to the translocation of itself and GSK-3 to the D2DR
complex. LY379268, mGluR2/3 agonist activates the mGluR2/3 resulting in an
upregulation of Dvl-2. The increase in Dvl-2 leads to recruitment of itself and GSK-3
to the mGluR2/3 complex. LY379268 also effects D2DR signalling leading to an
increase in Dvl-3 protein levels. The increase in Dvl-3 levels facilitates the
translocation of GSK-3 to the D2DR complex. Dvl-3 is also involved in the increase
in phosphorylated Akt levels, resulting in the phosphorylation of GSK-3. Dvl-3
and/or Dvl-2 interference of the “phosphorylation complex” inhibits GSK-3 ability to
phosphorylate β-catenin resulting in an increase in β-catenin protein levels. The
stabilization of β-catenin leads to its translocation into the nucleus, where β-catenin
interacts with TCF/LEF to initiate gene transcription.
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D2DR signalling leads to the upregulation of Dvl-3 protein levels, resulting in the
recruitment of GSK-3 to the D2DR complex. Dvl-3 is also involved in the increase in
phosphorylated Akt levels, resulting in the phosphorylation of GSK-3. Dvl-3 and/or Dvl2 interference of the “β-catenin phosphorylation complex” inhibits GSK-3 from
phosphorylating β-catenin, ultimately leading to the accumulation of β-catenin. βcatenin translocates to the nucleus and binds to TCF/LEF to alter gene transcription.
Regulation of Dvl-3/Dvl-2 at the protein level and its association with receptor
complexes appears to mediate the downstream effects on both the Wnt and Akt pathway
following antipsychotic/LY379268 treatments. Our results are consistent with a recent
study showing that altered Dvl protein levels, Dvl polymer formation and the
translocation of Dvl to receptor complexes is responsible for changes in downstream
signalling events in the Wnt pathway1. In vitro studies have also shown that increases in
Dvl-3/Dvl-2 protein levels lead to the stabilization of β-catenin and consequently the
activation of TCF/LEF transcription2, 3.

The translocation of Dvl to the plasma

membrane and the formation of Dvl polymers at the plasma membrane correlates with
Dvl ability to activate β-catenin signalling4, 5. Dvl-2 overexpression studies have shown
that an increase in Dvl-2 protein levels is sufficient to cause the translocation and
polymerization of Dvl-25. Based on our studies, it is anticipated that the increase in Dvl3/Dvl-2 and its translocation to receptor complexes (D2DR and mGluR2/3 complexes
respectively) induced by antipsychotics/LY379268 leads to the formation of Dvl
polymers, which is necessary for further signalling. Further studies will be needed to
validate this hypothesis.
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The model also shows that antipsychotic/LY379268 treatment recruits Dvl-3/Dvl2 and GSK-3 to the D2DR/mGluR2/3 complex, leading to the stabilization of β-catenin
levels. Others have reported that recruitment of Dvl to Fz/LRP6 is responsible for the
translocation of Axin-GSK-3 to the receptor complex following stimulation of the Wnt
pathway by a Wnt ligand6-8. Although the Fz receptor is known to activate the Wnt
pathway, several studies have shown that other GPCR may also regulate Wnt signalling
and that the stabilization of β-catenin and subsequently activation of ΤCF/LEF
transcription can occur through GPCRs independent of the Fz receptor. For example,
signalling through the gonadotrophin releasing hormone receptor9, parathyroid receptor10
and the prostaglandin receptor11 have been shown to regulate β-catenin. Therefore,
activation of the Wnt pathway following antipsychotic/LY379268 may occur through
D2DR and mGluR2/3 independent of Fz.
Understanding how antipsychotics or mGluR2/3 agonists improve the positive
symptoms of schizophrenia could provide alterative therapeutic targets that are more
effective and have fewer severe side-effects than traditional antipsychotics. Furthermore,
understanding how antipsychotic drugs or mGluR2/3 agonist alleviate psychosis may
provide insight into the manifestation of the positive symptoms of schizophrenia. One of
the most interesting findings of the study was the common and specific (i.e. not
mimicked by other drug classes) response haloperidol, clozapine and LY379268 induced
on Dvl-3 protein levels. Thus, Dvl-3 may represent a potential therapeutic target for
alleviating psychosis. Furthermore, Dvl-3 may be a more appropriate target than GSK-3
since GSK-3 is involved in multiple pathways throughout the body12. For example,
GSK-3 plays an important role in glycogen metabolism by phosphorylating glycogen
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synthase. Thus targeting GSK-3 may lead to metabolic disorders. In contrast, Wnt
signalling (i.e. Dvl) does not effect glycogen synthase activity13. Pathway specificity is
another issue since drugs that target GSK-3 must effect the pool of GSK-3 that
participates in Wnt signalling. Lithium and valproic acid are inhibitors of GSK-3 that do
not effect β-catenin signalling in the PFC and have no effect on the positive symptoms of
schizophrenia. Therefore targeting Dvl-3 may provide more selectivity and specificity
than GSK-3. Unfortunately, there are currently no commercially available inhibitors of
Dvl-3 to test in animal models of schizophrenia and Dvl-3 knockout mice do not survive
past weaning.

5.3 LIMITATIONS OF THE MODEL AND FUTURE STUDIES
One of the main findings of the thesis is that D2DR signalling regulates Akt and
the Wnt pathway. However, the current and previous studies have shown that D3DR also
regulates the phosphorylation state of Akt14. In the proposed model it was shown that
antipsychotics regulate Akt through the D2DR and that D3DR either has no effect or
contributes to D2DR regulation of Akt as previously described14.

Antipsychotics have

some affinity for the D3DR15 and thus it can not be ruled out the D3DR does not effect
Akt signalling. However, the data does suggest that activation of Akt by antipsychotics is
mediated by Dvl-3. In Dr. Rushlow’s laboratory it has recently been observed that Dvl-3
is associated with D2DR3 and not with the D3DR (data not shown) suggesting that
antagonism of the D2DR by antipsychotics regulates Dvl-3 leading to changes in the
phosphorylation state of Akt. One of the limitations of the model is the presumption that
Akt and Dvl-3 are localized at the same D2DR complex. Future experiments will have to
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be performed to determine if Dvl-3 and Akt co-localize to the same D2DR complex.
Unpublished co-IP experiments that were performed showed an association between Dvl3 and Akt suggesting that both are indeed co-localized. However, the antibodies available
for Dvl-3 and D2DR are not adequate for immunohistochemistry and thus we were not
able to confirm co-localization using confocal microscopy or by other techniques. Efforts
are being made to develop new Dvl-3 antibodies that can be used for
immunohistochemistry to address this problem. Furthermore, co-IPs experiments can
also be performed to determine if the association between Dvl-3 and Akt is affected by
antipsychotic treatment.
Mechanistically, the model depicts Akt phosphorylating GSK-3 at the D2DR
complex following antipsychotics/LY379268 treatment. Although from the protein
extracts there is an increase in pAkt and pGSK-3 it has yet to be shown that this change
in phosphorylation occurs at the D2DR complex. Future studies examining a change in
pAkt and/or pGSK-3 at the D2DR complex will be need be conducted. If there is indeed
a change in pAkt and pGSK-3 at the D2DR complex, this change in phosphorylation state
at the D2DR may have functional consequences for D2DR activity. GSK-3 has been
shown to effect the activity of the co-receptor for the Wnt pathway, low density
lipoprotein receptor-related protein 6 (LRP6) via phosphorylation16,
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.

Thus, the

association between GSK-3 and the D2DR suggests that GSK-3 may influence the
phosphorylation state and hence activity of the D2DR. Additional experiments will need
to be conducted to determine if this is the case.
Although the study showed that antipsychotic/LY379268 treatments increased
Dvl-3 protein levels it is unclear how antipsychotics/LY379268 cause an upregulation of
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Dvl-3 levels in the first place. There are several mechanisms that could explain how an
increase in Dvl-3 levels occur including the stabilization/degradation of Dvl-3 or changes
at the transcriptional level of the Dvl-3 gene.

Degradation of Dvl-3 through an

ubiquitination pathway is facilitated by prickle-118.

It has been shown that the

downregulation of prickle-1 correlates with the upregulation of Dvl-3 and the
accumulation of β-catenin in hepatocellular carcinoma cells18. Alternatively, changes at
the transcriptional levels could result in an increase in Dvl-3 levels. Unfortunately, the
Dvl-3 promoter has not been well characterized and its unclear what elements regulate
Dvl-3 transcription.
The consequence of increasing Dvl-3/Dvl-2 by antipsychotics/LY379268
treatment is the stabilization of β-catenin levels. Within the Wnt pathway, β-catenin is a
co-transcription factor that interacts with TCF proteins to regulate Wnt-mediated gene
transcription19, 20. In addition to its role in the Wnt pathway, β-catenin also participates in
the formation and maintenance of synaptic junctions

. Changes in β-catenin levels at
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synaptic sites can influence both the size and strength of synapses22 and alternations in
synaptic structure have been observed in patients with schizophrenia23. Thus, it is
possible that the increase in β-catenin levels following antipsychotic/LY379268
treatment may also effect synaptic functioning. Although, the thesis did not directly
address the consequence of β-catenin stabilization, results from our laboratory do suggest
that increases in β-catenin following antipsychotics/LY379268 treatment likely lead to
alterations in TCF-mediated transcription. For example, increases in Dvl-3/Dvl-2 protein
levels, as observed following antipsychotics/LY379268 treatment, has previous been
shown to be sufficient to activate TCF-transcription2, 3.

Furthermore, antipsychotic
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treatment induces the translocation of β-catenin to the nucleus, an event tied to changes
in TCF-mediated transcription24. To confirm that antipsychotics and LY379268 activate
TCF transcription, TCF-reporter mice may be used in the future.
Some target genes of β-catenin have been identified but most are associated with
cancer or development, two major fields of investigation in Wnt signalling, and
consequently little is known about TCF target genes that may be relevant to
schizophrenia. However, it has been shown that connexin 30 and 43 transcription are
regulated by β-catenin and connexins have been associated with schizophrenia.
Connexins are transmembrane proteins that assembly to form gap junctions and play an
important role in intercellular communication. Although there have been no reports on
connexin 30 or 43 and schizophrenia, connexin 50 has been identified as a susceptibility
gene for schizophrenia25.

Thus, studying the effects on connexins following

antipsychotics and in animal models of schizophrenia may be of interest. Identifying
genes mediated by β-catenin following antipsychotic and LY379268 may help to further
understand the role of the Wnt pathway in antipsychotic drug action.
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